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Abstract 
Oesophageal cancer is ranked amongst the top three most common cancers affecting black 
South African males. Only about 20 % of patients diagnosed with this disease survive beyond 
two years because the cancer is typically diagnosed at a late stage and resistance to therapy 
commonly develops. Chemotherapeutic agents such as cisplatin, doxorubicin and 5-
fluorouracil are currently used in the treatment of a variety of cancers, including oesophageal 
cancer. Although these agents have been part of our therapeutic repertoire for many years, 
there are several side effects that have been associated with their use in cancer therapy. Thus 
there is a need to develop novel chemotherapeutic agents with improved activity and less 
severe side effects. In this project, twelve compounds, consisting of 5 platinum dichloride 
complexes, four iminophosphine ligands and three gold (I) chloride complexes that were 
synthesised by a PhD student in our laboratory were tested for anticancer activity and the 
mode of action of these compounds was also explored. The cell viability assays revealed that 
the gold (I) compounds were most potent, when compared to the platinum compounds or the 
free ligands, with ICso concentrations ranging from 5 to 30 JIM. Only modest changes in cell 
morphology were observed in the cells treated with gold (I) compounds and a decline in cell 
migration was observed for compound 95 only. The decline in cell number was associated 
with DNA damage (assessed as an increase in yH2AX) and an arrest in the cell cycle at the S 
phase. Treatment with the gold (I) compounds led to the inhibition of Thioredoxin reductase 
activity, suggesting that ROS levels in the cells had increased. Furthermore, treatment with 
the gold compounds was associated with the induction of apoptosis. This suggests that the 
gold compounds blocked cell proliferation by processes that involved the production ofROS, 
DNA damage and the induction of apoptosis. Treating CXCR2 and IGFIR knockdown cells 
with the novel compounds did not improve efficacy against the cancer cell lines. 
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Oesophageal cancer 
1.1 Epidemiology 
Chapter 1 
Presently, cancer is the second most common cause of death globally, affecting both 
developing and developed countries with no definitive cure. I In 2008 an estimated 12.4 
million cases of cancer were diagnosed worldwide and 7.6 million cancer deaths were 
reported. More than 70 % of these deaths occured in developing countries.2 
Oesophageal cancer (OC) is ranked amongst the top ten most common and lethal cancers in 
the world.3 The incidence of OC differs geographically and with ethnicity, where high 
frequencies have been reported for certain parts of China, Iran, South Africa, France and 
Italy.4,s In 2002 China and South Africa had the world's highest age standardised incidence 
rates for this disease of 27.4 and 19.7 per 105 population, respectively. Furthermore global 
statistics indicate that males have higher susceptibility to OC than females (as seen in 
Figure 1).6,7,8,9 
Oesophageal cancer is the third most common cancer affecting South African males and the 
most dominant cancer amongst black South African males. lo The Transkei region (Eastern 
Cape) of South Africa has one of the highest incidence rates in Africa. 10,1 I 
A study conducted in 10 magisterial areas around the Eastern Cape and Kwa-Zulu Natal 
(1998 - 2002) revealed the age standardised rate for all cancers to be 72.8 per 105 in males 
and 59.1 per 105 in females. Oesophageal cancer accounted for 31.3 per 105 in males (43 % 
of all cancers) and 18.0 per 105 in females. 12 
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ESTIMATED NUMBER DF NEW CASES AND DEATHS FOR 
OESOPHAGEAL CANCER I TltOUSANDS (WORLD STATISTICS 1999) 
., InCldencc .. Mort"ltty 
Bolh Malel femalcs 
------ -------
Figure I: Comparison of incidence and mortality rates in males and females for 
oesophageal cancer worldwide. Male, have higher ,u,ceplibilitj' to OC than females (21 3 
per 10" in males and 103 per 10' in femalesl_ But both sexes have extremely high mortality 
mte" Numerical figures were adapted from ParKin N ai, (Global cancer statistics 1999).!l 
1.2 Histology 
Oesophageal cancer exists in two histological subtypes. adenocarcinoma (AC) and squamous 
cell carcinoma (SeC), 1,1l,14 Ad~nocar~inoma is more common in the IJSA; while squamous 
cell carcinoma. whidl con'titute, more than 80 % of all oe casc, worldwide i, mo,t 
prevalent in developing (.(Iuntrie,.1 5 This srudy focuses mainly Oll sec \~hich is the major 
histologi~al ,ubtype found amongst black South African males, 
sec develops from the middle or the lower third of the ocsophagus (Figure 2A), 6, 10 The 
tumour develops from the inner layer (epithelial cell,) of the oesophagus and invade, deeper 
into the oesophagus as it ('[Hltinues ![) grow (Figure 2B). The poor diagno,is a",ociated with 
see lead, to very few treatment options and a vary ing 5 year survival rate of 10 - 20 % 
depending on the tllmour stage of developrncnt and the patient" s response to therapy .'-17, 11_1' 
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Figure 2: SectiOIl of the oc,"'pha8us prone to file development "f ,' quaDlolls cell 
carcinoma (SeC). (A) The four epi!hdiallay~r\ ,,[the oesophagus ~l1d mrrollnding "'-gal'", 
(H) sec ufthe ocsophagu<, 
lfigure (AJ adopted I'mm (http://,...,,,'W.p n~~r.g:o;kaocq(oQiys,\'i\'nlkksQrh~gu s/r~ gd) 
and fig.lIre ell) modifIed from (h!lp;/ldj !l.~S1iv~d i"'·l"".Ulh,~"".cdu/c\llpha ~~~ISlen!.nsp) J 
, 
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1.3 Therapeutic approaches 
Generally, in developing countries, only 20 % of patients with oesophageal cancer would 
qualify for curative treatment (which includes radiotherapy, surgery and chemotherapy) while 
the other 80 % are suitable for palliative therapy (for example brachytherapy and stent 
placement) because of the late stage of diagnosis in most cases. 35,36 Palliative treatment, 
involves inserting a stent or tube into the oesophagus to prevent it from closing as a result of 
tumour growth. 
Because of the aggressive nature of oesophageal cancer, it is important to develop strategies 
aimed at reducing morbidity and mortality associated with this cancer. This may be achieved 
by reducing exposure to risk factors that are associated with the development of oesophageal 
cancer and these include the consumption of extremely hot beverages, local dietary and 
cultural practices and a combination of tobacco smoking and alcohol. In addition diagnosis of 
OC at an early stage increases the likelihood of successful treatment and lastly by adopting 
better therapeutic approaches, through the development of effective chemotherapeutic agents. 
As part of the drug development process, natural products from a wide range of sources 
(plant, algae and marine invertebrates) and chemically synthesised compounds, have been 
investigated for anti-tumour activity to produce more effective chemotherapeutic agents. In 
most cases, during cancer therapy, pharmaceuticals are used in combination with 
radiotherapy, surgery and other strategies aimed at palliating the effects of OC. 
5 
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Due to the complications associated with surgerr2-24, combination therapy is considered 
more effective than monotherapy. If the tumour has metastasised, surgery alone may not be 
beneficial and thus adjuvant or induction therapy is required post or prior surgery.25 In cases 
where the cancer has spread to the lymph nodes, radiotherapy is necessary post-surgery to 
minimise the risk of recurrence.26 Chemotherapy is usually administered prior to surgery. 
Currently available drugs include many forms of natural derivatives and inorganic 
compounds. However these compounds have been associated with several side effects and 
this is a major drawback in cancer therapy. 
1.4 Natural products 
Thirteen years ago, Cragg et al. (1997) pointed out that more than 60 % of anticancer agents 
in current use then were natural product derivatives. 27-29 Natural derivatives are synthesised 
from secondary metabolites (usually toxic) which often function as a self defence mechanism 
for the organism against herbivores, pests and pathogens. However, some of these secondary 
metabolites may also contribute odours, tastes and colours in plants.3o Secondary metabolites 
may be extracted from any part of the organism. 31,32 Many of the secondary metabolites are 
derived from aromatic amino acids or shikimic acids, which are precursors of alkaloids and 
other aromatic metabolites.30,33 
Some examples of natural product derived cancer therapeutic agents include compounds such 
as podophyllotoxin (Figure 3A), Vinca alkaloids (Vincristine) (Figure 3B), taxanes 
(paclitaxel) (Figure 3C), camptothecin and their derivatives. Some of these compounds are 
still in use to date as cancer therapeutic agents. 34,35,36 
6 
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(B) il· Me, V,nbLui"'" 
il_CHO, IIIncn.hn~ 
figure 3: Stnrctures of some ch~mothe,-apeutic agents derived fwm natural product 
sources_" 
Although s(~,..., natural products have yielded very effective anticanc~r drugs, therc arc some 
concerns associated with the usc of namral products for drug development in medicine. n-.c,e 
include scarcity of resoo"c~<, habitat loss and degradation, as well as over·harvesting ofthe_", 
",,,m,-ees. J7 In addition to this, a study C{mducl~d by William ~I ai, (2009) indicated that 
climate changes in the marine world may lead to locHI extinction of _'peci~, in ,orne r~giom 
",sulling in a change in biodiver<ity d~ to ,pecic, recii,tribulion, J! Other concerns include 
the ability to con\er;'e knowledge of known medicinal p'"()peni~, of local natural SOurces 
while making the ;nfmmation mOre widely accessible JJ 
, 
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O"er the ra;1 decades there has been a decline in the production of natural phannaceuticals in 
general as is evident in Figure 4 when compared to the 60 % reported by Cragg er al. (1997), 
thineen years ago. However it is evident (as seen in Figure 4) that natural products have been 
a prototype in the synthesis of many novel GOmp<1llJl(Is.2~9~9,4G From 1981-2006, a total of 
11 84 compounds were derived from dilTerent sources in which 100 of these were anticancer 
~ gcnts (Figurc4), ,9 
ANTICANCER DRUGS 11981-2006l BY SOURCE 
. S . N . ND . S :;; S/NM . S' . S'/NM . V 
Figure 4 : Anticancer compounds synthcsised from 1981-2006, categorised hy sourcc. 
(N- lOO). Codes are as in reference 50, 8- biotogical source, N- natural product, NO- derived 
from natural product, S_ totally synthetic from random screening, S*- tota lly synthetic with 
natural product pharrnocophore, NM- Natural product mimic, V- Vaccine. 
Fortunately there are a significant number of effeL1ive cancer therapeutic agents that have 
been dcve10pai through chemical synthetic processes that do not involve natural products, 
Many of these compounds are currently still in use clinically, suggesting that this route to 
drug development may still hold promise fo.- development of new and effective cancer 
chemotherapeutic agents, Furthennore, unlik~ !lamral products which were as<()c.iUlCd wilh 
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scarcity or rCSOUr~CS and low p,uduct yield, s}l1tiletic agent, "''' mo,-" advantageou, hecause 
prodllCtion is in bulk and there is large v,,,,iation ofre"ourcc and pnlduct. 
1.5 Inorganic compounth 
The platinum complex cisplatin (c!s-diamminedichlotidoplatinum(ll» (Figurc Sa) and it, 
second and third gcneration analogues, carhop latin-
(ds-diamminc( I, I_cyclobut~nedica..tx)x ylato )platintlm(ll» (Figurc 5b). and oxaliplalin 
(Ira!ls_R,R_cyclohexane_(l,2_diamine}oxalatopJalinum(IJ)} (figure 5c) represent a family of 
metal ~om)Xlunds that have proven to be extraordinarily useful as chemothernpeutic ~gents 
and arc still in ~u!Tent u,e against ,everal cancers glob~lly, <!_n 
H"N" rCI )', 
HsN CI O~ NH2" ,P-c?O ! "PI-.. i NH2 ~o 
{AI Clop""" I'J (el o ... ,;p .. .., 
Figure 5: Structures of p latimlm compounds used as cancer cilemotherapeutic agenls.4• 
Current evidence inlhc literature suggests tilat ci~lalin ha , been One of' the most commonly 
lIscd therapeutic ~gent' in the trcatment of oesophageal ~ancer, with its u.,e continuing to 
date.4J.' S-4! Cisplatin ~ctivity i, dependent On thc chloride concentration, In tile blC>CJd the 
chl(\!ide concentralion is ~oout 100 ruM and thus ci'platin i., only slightly aClivc. Insidc the 
cell tnough, the concentration is much lowe" (3 mO.-I) leading to the complete activation or 
cisplalin,4' Once in a low chloride aqueous solution, the ~hloride separates f!"Om platinum and 
lhc actil'c platinum react, with nucleophilic groups present in the amino acid side chains and 
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purine bases of D:'>IA and RNA.49,50 Cisplatin interacts with DKA forming DNA adducts. It 
has be~n suggested that only I % or cisplatin reacts with D:'>IA, forming DKA addu<:ts whil~ 
the rest reacts with other cellular components such as Rl'lA, proteins. mernbrnn~ 
phospholipids, cytoskeletal microfilamellls, and thiol-containing molecules. 11--'< 
DKA adducts result from different types of cross-links as jlJustrated in Figure 6, formed as 
cisplatin reacts with DNA The 1,2 intraSlrand crD5s-Jink [cis-Pt(NHJ):'d(pGpG)] (Figure 6b) 
occounts fin 65 % of the total cisplatin-DKA adducts formed while only 25 % are atlribut~d 
to the 1,2 inlrastrand cross-link [cis-Pt(NHJ):,d{pApG)] (Figure 6c)H4J,Sl,l> 
rigu re 6: Cro.s-linkiog of dsplatin "jlh DNA. (a) Intrastrand cross-link (b) 1,2 intrastrand 
cross-link (c) 1,2 imrastrand cross-link (d) protein- DKA cross-link,'" 
The D:'>IA adducls ar~ repairnl by nuckot"le excision r"Pair (NER), but l)O(ll' D'IA r~p~ir 
results in the form~ t ion ofD:'>IA douhle str~nd hreaks which induce ~dl ~ycle arre,L Ci'pialin 
then ~x~rts its cytotoxicity by inhibiting D.'IA synthesis and initiating apoptosis via the 
p5J/p73 pathways, which are regulatory pathways that cdls employ to monitor the integrity 
of g:enomic DKA.4 1 ,56~7 
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Despite the side effects such as nephrotoxicity, nausea and vomiting, cisplatin remains a 
widely used chemotherapeutic agent for solid tumours.58 Given its success, several other 
platinum based anticancer complexes have been synthesised and tested in clinical trials and 
some (eg.carboplatin) have been shown to be more stable than cisplatin.4l,50,59 Aside from the 
side effects described above, one other major drawback associated with platinum-based 
treatment is drug resistance which has been shown to be induced via several mechanisms.49,60 
These include decreased intracellular drug accumulation and increased induction of 
intracellular thiols (glutathione and metallothionein), which are synthesised when cells are 
subjected to stress or in response to accumulation of heavy metal ions.49,61,62 DNA repair has 
also been implicated in contributing to drug resistance as a result of an up-regulation of DNA 
repair proteins. A study conducted by Chu et aZ. (1990) showed an increased expression of 
the DNA repair protein, xeroderma pigmentosum group E binding factor (XPE-BF), in 
cisplatin resistant cells when compared to normal cells.63 More recently, other non-platinum 
based compounds have been synthesised and tested for anticancer activity and these include 
ruthenium, titanium, iron, cobalt and gold complexes.64-68 These novel metal-based 
compounds may kill cancer cells by different pathways than cisplatin, thus increasing the 
repertoire of drugs at our disposal for treating patients with cancer. 
1.6 Gold compounds 
Gold exists in 7 different oxidation states and only gold (0), gold <n and gold (III) are stable 
under aqueous and biological conditions. 69 Because gold <n and gold (III) are readily 
reduced by mild reducing agents they are less stable than gold (0). Furthermore, gold (I) is 
thermodynamically more stable than gold (III) even though they are both soft cations with a 
high affinity for soft ligands.69,70 Evidence in the literature suggests that gold compounds are 
11 
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transported b} binding [0 Cy,34 or albumin. The proces, im'olves [he WmerSIOll of gold 
complexe, to albumin complexe, [Albumin-S' + Er.,PAuSAtg » Albumin-S-Au-Pet3 
AtgSH]throogh a series of oxidative reactions that see the gold molecule interading with 
sclenocnzymes leading to its cytotoxic effects. 10,71 
Gold (I) compounds have a d lo closed-shell configuration, which allows linear. trigonal and 
tetrahedra I coordination.1O 
('hiolates and phosphine complexes rep resent the most inv~ stigated gold (I) phannaceuticals, 
AUraJ1ofin, a pho,phinegold (I) thiola[e complex used to treat rllCumalOid arthrili" wa, also 
found to po,se" an(i(umour activity. 72-" Auronofin induces its cytotoxic eilcct by inhibiting 
,c!enocnzymes such as Thioredoxin reductase. This leads to mitochondrial membrane 
permeability. the release of Cytochrome c and e,'entually apoptosis,1, 
Figure 7: Structure of Auranofin.76 
('he discm-er} or the anticancer properties of auranofm lead to the synthesis of many other 
gold (!) compounds. such a, [Au(PPhl)(Hxspa)] and [AuPPh)l2(xspa)], which have been 
te,ted tor anticancer activity and found to bave cytotoxic erred, on cancer cellline,.71.18 
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Gold (lll) complexes display structural similarities to platinum (n) complexes (as seen in 
Figure 8) because they are i"",lectronic (d! configuralion) and lhey PO""'" ,quare-planar 
geometries and thus gold (Ill) complexes have also been invcstig~tcd for their ~nlicancer 
propertie" ,j 
(A) [A~DMDTICI:I (S) [Ao(DMDTIBrd ee) Cispletin 
Figure 8: Slructuml representation of go ld (TTl) compounds (A and B)6j and plminum (ll) 
compound ci'plmin (C) 
Gold (1Il)-dithiocarbamato derivatives such a, [Au(DMDT)CI,1 (Figure 8A) and 
[Au(DMDT)Br2J (Figure 8U) have neen found to ne more aCli,' e lhan ci,plmin (Figure 8C) 
and were al", obsened to he cytotoxic to cisplatin resistant cells, suggesting that although 
similar to cisplatin in sl~ture. they induce their anlicancer activity 'iia a m..chani,m 
different from thaI of ci,platin." Dithiocamamate, are bidentale chelaling ligands thaI are 
very stable OnCC complcxed to the metal ion. due to their chelating effect. The presence of a 
chel~ting dithiocamamalo i, said to conlribu\C 10 the reduced nephrotoxity of the compounds 
due 10 their minimal interaction with thiol cOlllaining biomolcculcs." Regardless of the 
,tructural ,imilarilics, gold (Ill) dithiocarbamato complexes exert their amicancer acli"ily 
lhrough a mechani sm d iITerenl ti-om thai of platinum (H) compound" Instead of targeting the 
D:"<A and forming Dl\A adduct'. gold (III) compound, largel the prOicasome. Inhibilion of 
the proteawme lead, 10 the accumulation of ubiquitinated pmteins, an up-regulation of p27 
(inhibitor of the cell cycle) and an induction of apopto,i" Wi! 
Un
ve
rsi
ty 
of 
Ca
pe
 To
wn
This indicates that metal-based chemotherapeutic agents exert their effect by activating a 
variety of biological pathways ultimately leading to cell death. An understanding of the 
mechanism of action of these compounds may facilitate the development of more effective 
chemotherapeutic agents. 
In a previous study conducted in our laboratory, a fellow student (Dr. Harry Chiririwa) had 
synthesised a series of metal-based compounds that were further characterised in this project 
to better understand how these novel compounds induced cancer cell death. In the next 
section of this review, we considered some of the biological pathways frequently affected by 
chemotherapeutic agents, to provide a background for some of the studies that were 
conducted in this project. 
Tumour cells are characterised by deregulated cell proliferation and suppressed cell death and 
both these processes involve the activation of several complex pathways. 8~2 Therapeutic 
agents induce cell death in cancer cells via apoptosis, necrosis or autophagy (as seen in 
Figure 9). Generally in the literature, there has been a tendency to develop cancer therapeutic 
agents that induce cell death via apoptosis and not via necrosis (which is associated with the 
induction of inflammation) or autophagy (which has been implicated in promoting survival of 
cancer cells under stressful conditions).83-85 The mechanisms that lead to the activation of cell 
death involve a wide range of processes including the generation of reactive oxygen species 
(ROS), cell cycle arrest, mitochondrial dysfunction or the alteration of pro-apoptotic and anti-
apoptotic proteins. Therefore, when characterising novel therapeutic agents, it is important to 
identify and understand the pathways by which these agents induce cell death and inhibit cell 
proliferation. 
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Figure 9: Dlagrlllnmatic representation of some of the lIathwa~ that lead 10 cell death 
in cukaryoles. Three modes of cell death are represented. Apoptosis may be initiated through 
the activation of death receptor, (TNFR'TRAIL-R) or via the mitochondria. leading to the 
release of Cytochrome c (Cytc) and the aLl1vation of easpases (Casp) whkh cleave Poly 
(ADP-ribose) Polymerase (PARP). Similarly the activation of ""ath r..cepto[l< leads to the 
activation of several other processes such the recruitment of the adaptor molecule FADD, 
leading to the a<-'\ivation of caspases. The mitochondria are mso responsihle for inducing 
necrosis via ROS produ<-1ion or tll<: activation of Apoptosis inducing factor (AIF). An 
autophagic response may be initiated in the endoplasmic reticulum (ER) and this leads to the 
activation of downstream effectors such a' Bedin. 
Figure obtained from, htlP:i;"'_'H'.:.wedscapc.~om/vie" altide/54(j~').' 2 
1.7 Autophagy 
The uhiquitin-protcasome and autophagy syslems am e5Sential for maintaining balance 
between bio'ynthetic and d~gradative processes for normal cell growth and development. &<! 
Autophagy is essentially a survival mechanism. When cells undergo nutrient and growth 
fal10r depletion. cells exit the cell cycle and aulOdigest long-lived proteins and damaged 
organell e.,. This leads to the r~~yding 01 lipid ~ , carbohydrates and amino acids, to produce 
macromolecules or to fllcilitat~ o~idati()11 il1 the mitodlOtxlria to maintain cellular ATP.!).'" 
Tll<:refore if autophagy is used as a strategy by cancer cells to escape the cytotoxic effu'Is of 
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therapeutic drugs, blocking this pathway with specific drugs may provide an attractive 
approach to kill cancer cells.85 Decreased expression of Beclin-l, a marker for autophagy, has 
been associated with the development of a tumourigenic phenotype.85 Further more, an 
increase in Beclin-l expression has been shown to inhibit cell proliferation and decrease 
tumourigenic potential.86,87 However, the information regarding the role of autophagy in 
tumourigenesis and therapy is controversial 88-91 and thus experimental evidence requires 
careful analysis. 
1.8 Apoptosis 
Apoptosis or "programmed cell death" is an essential process in development and in 
maintaining homeostasis in self-renewing tissues of normal cells. Defects in this process 
could prolong the life span of cells, a condition associated with neoplasia.92,93 Apoptosis may 
be initiated via the activation of death receptors such as Tumour necrosis factor receptor 
(TNFR) or TNF receptor super family member (F AS), mitochondrial dysfunction or via ROS 
generation.92,94 The initiation of apoptosis via death receptors involves the activation of 
adaptor proteins such as F ADD in the presence of stimuli (therapeutic agents or irradiation). 
This then leads to the activation of caspases 811 0, which further cleaves other caspases and 
target proteins to induce apoptosis (as seen in Figure 9).94 As previously mentioned, 
apoptosis may be induced via the mitochondria as a result of a build up of ROS or through 
the alteration of pro and anti-apoptotic proteins (Figure 9). This is associated with the release 
of Cytochrome c which activates Apafl and Caspase 9, leading to the initiation of 
apoptosis.95 
The process of apoptosis is divided into early and late stage apoptosis.96,97 A study conducted 
by Prete et al. (2002) suggested that mRNA degradation is an early stage apoptotic event that 
16 
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is ~ommOn to all apoptotie pathways," Il1e process of apoptosis is ad~nosine triphosphate 
(ATP) dependent and evidence in the literature suggests lhat ATP d~pldion and lo,s of 
membrane integrity occur during lale 'lag~ apopto>i,y,'J,9~j03 As part of thc pracc,," of 
apoptosis, a nuel~ar proldn poly (ADP·ribo,e) polymerase (PARP) is typically 
proteolj'lieally deaved, generaling a 89 kDa fragment from a 116 kDa precursor fonn, Both 
tl..., precuT>or and thc dcaved products are detectable by Western biOI analys is, l'''. _ LUO 
1.9 The mitochondria 
In addition to generating AlP, the mitochondria pia;.' a cru~ial role in maintaining Ihe ~dlular 
redox ,late, calcium levels and fae·i I itating apoplo5is.91,IO ' .. liD Deregulalion of any of the,e 
proce,,,,, will lead to a change in mitochondrial m~mbran~ pol~nlial (LI,!,). Furthermore. 
deregulation of pathways that are responsibl~ for maintaining thc cellular redox ,late may 
lead 10 mitochondrial damage and elevated ROS l~vd,.101' Gold compounds havc been shown 
to alter the mitochondrial membrane p(){ential (LI",) by inhibiting th iols (such as '],hioroooxin 
reductas~) lhat are cs>cntial tor regulating ROS levels (Figure 11). 
Figure 11: The Thioroooxin retludase system. Reduced NADPII initiates the redu~lion of 
I'hioredoxin rooucla,e (TrxR ~ SeH) which leads to the reduction of Thioredoxin (Trx) and 
Peroxiredoxin (PIX). Prx is a ROS scavcnger, lhe reduced fonn oftl..., proleins are indi~aled 
by Set Ii SI I and Ih~ oxidi,ed by SCiS,ll l 
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From Figure 11, it is observed that in the presence ofNADPH, Thioredoxin reductase (TrxR) 
facilitates the reduction of Thioredoxin (Trx), which in tum reduces Peroxiredoxin (Prx) 
which inhibits the build-up of hydrogen peroxide (H20 2). It has been proposed that gold 
compounds alter the Thioredoxin system by inhibiting the activity of Thioredoxin reductase, 
resulting in the rapid accumulation of oxidised Prx. The accumulation of oxidised Prx leads 
to an accumulation of H202 species, which increase mitochondrial permeability and this leads 
to the release of Cytochrome c and the activation of Caspases, ultimately resulting in 
apoptosis. III 
Other factors that lead to changes in mitochondrial membrane potential include the alteration 
of pro- and anti-apoptotic proteins, mediated by the Bcl-2 family of proteins. A study 
conducted by Shimizu et aZ. (1999) indicated that, in the presence of death stimuli, the pro-
apoptotic protein Bax trans locates to the mitochondrial membrane. There, it interacts with the 
voltage dependent anion channel (VDAC), leading to a loss of mitochondrial membrane 
potential (A'I') and the release of Cytochrome c. Furthermore, the study showed that the 
presence of Bcl-XL' an anti-apoptotic protein inhibited the interaction between VDAC and 
Bax and thus inhibiting the induction of apoptosis.112,113 In addition to mitochondrial 
permeability, the cell cycle also plays a major role in inducing apoptosis, as indicated above 
with cisplatin. 
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L1U Thf cell cycle 
The cell cycle (figure 12) is an llnJXlI!an! regulatory process in eukaryotes that is required for 
accurate duplication and transmission of DNA information from (he parent eell to daughter 
~db.U. The cell cycle consisw of DNA check points (GI and G2) (hat mooitor DNA 
integrity during cell divisiOll_ 'Ihe Rb/E2F transcription eomple.~ is located at the r~triction 
point of the cell cyclc. DNA replication OCClll"S at tim S phm;e and cell division, whieh re:sults 
in the formation of two identical daughler cells, occurs at the MIMitosi8 phase, In the absence 
of growth l"ricwrs or mitogen.<;, eells remain dormant or in the quiescent state (00) and onee 
rhe necessary chemi~al stimuli (growth faclors and mi(ogens) are present, the cells exit 00 
and enter into G I. '('he retinoblastoma (Rb) protein is then phosphorylated by eyelin D/cdks, 
leading to the dissociatioo of the RbiEl f complex and progression of the cell cycle .Il•·m 
Figure 12: Schematic rcprcscntatioo of the stages oflhe cell cycle , Thi, figure was ado r ted 
from (hnp:llwww.eC!ltergrove.kI2.in.uslcms/lib4ilN01OOO8S0/CentricitylDomaini 
SOO/Cell%2OCyde.jpgl 
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The Gl or gapl checkpoint, checks the cells for the presence of DNA damage or mutations 
before entering the S phase for DNA replication.81 The G2 checkpoint ensures that all the 
DNA was duplicated during the S phase and that the chromosomes are ready for separation 
into two daughter cells. The cell then enters into M phase. Cyclin dependent kinases (CDKs) 
are activated periodically and they are responsible for mediating cell cycle progression. I IS 
In cancer cells, cyclin D expression is frequently up-regulated and thus there are elevated 
levels of pRb, resulting in continuous cell division. Furthermore the Gland G2 check points 
are disrupted, giving way to uncontrollable cell proliferation and the transmission of damaged 
or mutated DNA to daughter cells. I 14,1 16 Chemotherapeutic agents often act by inducing DNA 
damage, thus inhibiting cell cycle progression. This cell cycle arrest is followed by DNA 
repair, however, if the DNA can not be repaired, apoptosis is induced. In many cases cell 
cycle inhibition has been associated with high levels of ROS which react with the DNA 
causing DNA damage. I07 
In this review, I have briefly reviewed some important biological pathways that are 
frequently activated by chemotherapeutic agents, eventually leading to cell death. I have also 
shown that the late presentation of oesophageal cancer is associated with a poor prognosis, 
with most patients having a life expectancy of less than two years at the time of diagnosis. I 17 
Thus there is an enormous amount of work that still needs to be done in improving cancer 
therapy. Therefore there is continuous need to develop novel, more effective and less toxic 
therapeutic agents. We propose that the synthesis and characterisation of novel metal-based 
complexes may hold some promise for the development of novel chemotherapeutic agents. 
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1.11 Aim 
The aim of this study was to screen several novel compounds for cancer cell growth 
inhibitory properties, to characterise their mechanism of action and to test their effect in a 
panel of cancer cell lines and normal fibroblast cells. 
1.12 Objectives 
1. Were to determine the cancer cell growth inhibitory activity of several metal 
complexes and their ligands against a panel of cancer cell lines, compared to normal 
fibroblast cultures. These compounds were synthesised by a PhD student (Dr Harry 
Chiririwa) at our laboratory. 
2. To characterise the mechanism of action of the active compounds. This objective was 
achieved by: 
o Testing for apoptosis 
o Testing for ROS generation 
o Monitoring DNA damage 
3. To determine the effects of the compounds on the cell lines where the CXCR2 and 
IGFIR pathways had been altered (WHCOI and WHC06 knockdown cells). The 
knockdown cell lines were prepared by Dr Luke Esau. 
21 
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Chapter 2 
Materials and methods 
2.1 Reagents and compounds 
For this project five iminophosphine ligands were synthesised (as shown in Figure 2.1) by a 
PhD student (Dr Chiririwa) at our laboratory, using o-diphenylphosphinobenzaldehyde as a 
precursor. The iminophosphine ligands were obtained at a yield of ~75 % and their structural 
representations are shown on Table 2.1. 
R = 2,6 IPr C6H3 60 
R = (CH2)C6H5 61 
H 
~/R R = (CH2)C5H4N 62 N 
R = (CH2)C4H3O 63 
R = (CH2)C4H3S 64 
o-dlphenylphosphlnobenzaldehyde 
Figure 2.1: The synthesis of novel iminophosphine ligandsl18 
Table 2.1: Structures of the ligands. 118 
60 61 62 
CC"l) 
63 64 
cc"U 
...... . 
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Iminophosphine ligands consist of 'hard' nitrogen and 'soft' phosphine donor atoms, a 
property that enables the ligands to bind soft metals ions such as Pt+2, Au+ and Ag+.118,119 For 
this project five platinum dichloride complexes were synthesised by reacting ligands 60 to 64 
with either Dichloro-(l,5-cyclooctadiene)-platinum(II) [Pt(COD)Ch] or Platinum(II) 
dimethylsulfoxide complex [Pt(DMSO)2Ch] as seen in Figure 2.2. Structures for the resultant 
complexes are shown in Table 2.3. The highest yield of 72 % was obtained for compound 84. 
Compounds 85 to 88 gave yields of 68 %, 70 %, 71 % and 70 % respectively. I 18 
R = (CH3) ... (CHhC6H. 
R = (CHz)C6HS 
R = (CHz)CsH.N 
R = (CHz)C.H3O 
R = (CHz)C.H3S 
Figure 2.2: The synthesis of novel platinum dichloride complexes 118 
Table 2.2: Structures of the platinum dichloride complexes I 18 
84 85 86 
cc:~ 0::;0) (X:NJ.) P'-~-CI N ~"-CI ptf Ph CI Ph" 'p" CI ptf Ph CI 
87 88 
et;~:o pI Ph Cf 0::;~:O Ptf Ph CI 
23 
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In addition to the synthesis of platinum complexes, two gold (I) chloride complexes were 
synthesised from reacting ligands 63 and 64 with Chlorotetrahydrothiophen gold (I) 
Au(tht)CI (Figure 2.3). Complexing the other ligands (60,61 and 62) with the gold metal ion resulted 
in the formation of insoluble gold complexes which could not be characterised further. 
R = (CH2)C4H30 
R = (CH2)C.H3S 
Figure 2.3: The synthesis of novel gold (I) chloride complexes 118 
Linear coordination for compounds 93 and 94 was confirmed by X-ray crystallography.118 
An additional gold (I) complex (95) was synthesised by reacting Au(tht)CI with 
triphenylphosphine, however this compound is not novel, like the other two compounds (93 
and 94). The structural representations for all three gold complexes are shown on Table 2.4. 
Table 2.3: Structures of gold (I) chloride complexes 118 
13 1M 15 
cc:n CCN:::O Ph, _Au-CI I ,4} P. ... :u-cp J I ,4} P. ... Au- ctS J P, Ph" Ph Ph" 'Ph Ph" 'Ph 
24 
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The components of the buffers used in the following section are found in 
appendix B. 
2.2 Cell culture 
The oesophageal squamous cell carcinoma cell lines (WHCOI, WHC05, WHC06, KYSE70, 
KYSEI50, KYSE410 and KYSE450), cervical cancer cell lines (CaSki, HeLa, SiHa and 
ME180) as well as two breast cancer cell lines (MCF-7 and MDA-MB-23I) and two normal 
fibroblast cell cultures (FGo and DMB), were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 100 U/ml Penicillin, 100 J1g1ml Streptomycin and 10 
% (v/v) heat inactivated Foetal Calf Serum (FCS) (GmCO, Paisley, USA). WHCOI, 
WHC05 and WHC06 cells were obtained as a generous gift from Dr. Vealel20 and the 
KYSE70, KYSEI50, KYSE410 and KYSE450 cell lines were obtained from Dr. Yutaka 
Shimada (University of Toyama, Toyama, Japan) and purchased from the DSMZ cell bank. 
The normal skin fibroblasts, FGo and DMB cells were obtained as a generous gift from Dr. 
A. D. Marais (Groote Schuur Hospital, Cape Town) and the other cell lines were purchased 
from the American Type Culture Collection (ATCC) (Rockvile, MD, USA). Cell cultures 
were maintained at 37°C in a humidified atmosphere of 5 % C02 and culture dishes were 
kept at 70 % - 95 % confluency. The cells were sub-cultured with 0.05 % (v/v) Trypsin-
EDTA solution and neutralised with DMEM (1:1 ratio). For long term storage, cells were re-
suspending in freezing medium [10 % (v/v) DMSO (# R36/38, MERK, Darmstadt, 
Germany), 20 % (v/v) FCS, and 70 % (v/v) DMEM] and Iml aliquots were frozen at -80°C 
before being transferred to liquid nitrogen. 
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2.2.1 Mycoplasma test 
To test for mycoplasma contamination, all cell lines were subjected to a mycoplasma test 
regularly. Cells were cultured in Penicillin and Streptomycin (PIS) free DMEM for one week, 
after which they were plated onto covers lips and incubated at 37°C overnight. Cells were 
fixed in fixative (1:3 glacial acetic acid: methanol) and stained with 0.5 J.1g/ml Hoeschst 
fluorescent DNA-binding stain (# 33258, Sigma, USA). The covers lips were mounted and 
visualised on the Axiophot fluorescence microscope (Zeiss, Germany). 
2.3 MIT assays 
2.3.1 ICso determination 
MIT [3-( 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is a Tetrazolium salt 
which is used to measure the metabolic rate of cells through the reduction of the MIT to 
formazan in the mitochondria of metabolically active cells. MIT assays were conducted on a 
series of oesophageal, cervical and breast cancer cells lines as well as on normal fibroblast 
cells. The experiments were conducted in 96 well plates in triplicate, for 8 different 
concentrations (see Appendix A for treatment tables). Cancer cells (3xl03) and normal cells 
(5x103) were plated per well in 90 J.11 DMEM and incubated at 37°C overnight. lOX drug 
concentrations in medium containing 0.2 % (v/v) DMSO (# D2650, Sigma, USA) were 
prepared in a concentration range as shown on the treatment tables (Appendix A). 10 J.11 of 
the lOX drug dilutions was added to the cells which were then incubated at 37°C for 48 
hours. Cells were observed under the Telaval 31 microscope (Zeiss, Germany) before they 
were incubated for 4 hours at 37°C with 10 J.11 of 5 mg/ml sterile MIT reagent (# M2128, 
Sigma, USA). Subsequently, 100 J.11 of solubilisation reagent was added to the cells and 
incubated at 37°C for 16 hours, to dissolve the formazan crystals. The absorbance were 
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determined at 595 run on the BioTek EL800 microplate reader (USA) using the Gen5 
software, readings were exported as an Excel file and the data was analysed using Graphpad 
prism. 
2.3.2 Cell growth assay 
WHCOI oesophageal cancer cells (1.5xI03) were plated per well in 90 J11 DMEM and 
incubated at 37°C overnight in 96 well plates. lOX drug concentrations were prepared using 
0.5X, IX and 2X the ICso concentration. After each time point (Time 0, 24, 48, 72, 96, 120 
hours after treatment) 10 J11 of MIT reagent was added to the cells and incubated for 4 hours 
at 37°C. 100 J11 ofsolubilisation reagent was added to the cells and incubated at 37°C for 16 
hours. The absorbance was determined at 595 run on the BioTek EL800 microplate reader 
using Gen5 software. Readings were exported as a Microsoft Excel file and the data was 
analysed using Microsoft Excel. 
2.3.3 Treating IGFIR and CXCRl knockdown cells 
MIT assays were conducted on WHCOI and WHC06 cell lines, either untransfected (wild-
type) or transfected with shRNA targeting Insulin-like growth factor receptor I (IGFIR) or 
CXCR2, or a control shRNA sequence (Ctrl). These stably transfected cell lines were 
generated by a PhD student in our laboratory (Dr Luke Esau). Prior to the experiments 
conducted in this project, the expression status of CXCR2 and IGFIR was determined by 
Western blot analysis and the results shown in chapter 5, for the WHC06 cell line were 
obtained by Dr Luke Esau in our laboratory. The experimental procedures were carried out as 
described above (2.3.1). 
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2.4 Cell morphology assay 
WHCOI cells (1xlOs) were plated in 60 mm plates and incubated at 37°C overnight. Cells 
were treated with IX or 2X the ICso concentration, for 12, 24 and 48 hours. After each time 
point pictures were taken on the Telaval 31 phase contrast microscope using the Mitocam 
2500, 5.0MP Live Resolution camera (Motic@, China). 
2.5 Cell migration assay 
WHCOI cells (lxl06) were plated per well in 6 well plates and incubated overnight at 37°C. 
A vertical scratch across the cell layer was made using a p200 pipette tip, after which the 
medium was changed to remove dead cells and detritus. 10 J1g/ml of Mitomycin C (# 4287, 
Sigma, USA), an inhibitor of cell proliferation, along with drug (lCso concentration) was 
added to the cells. The scratch width was measured at 0, 8 hours and 24 hours after treatment. 
For each condition 3 different views were captured using the phase contrast settings on the 
Axiovert 200M fluorescence microscope (Zeiss, Germany) and 3 different measurements 
were taken per view. 
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2.6 Cell cycle profile 
This assay was conducted in triplicate in 60 mm plates. WHC01 cells (3xlOs) were plated 
and incubated overnight at 37°C. Cells were treated with IX and 2X the ICso concentration 
for 12, 24 and 48 hours. Cells were harvested at the indicated time points by trypsinisation 
and centrifuged at 200X g for 5 minutes. The pellet was resuspended in 2 ml of media and 
cells were counted with a Telaval31 microscope using a haemacytometer. Cells were fixed in 
8 ml ofice-cold 100 % (v/v) ethanol (EtOH) and stored at -20°C for a minimum of 24 hour to 
a maximum of 2 weeks. The cells were pelleted by centrifugation at 200X g for 5 minutes. 
The pellet was washed in 1 ml 1xPBS and samples were centrifuged at 200X g for 5 minutes. 
The pellet was resuspended in 1 ml 1xPBS and an amount equivalent to the overall lowest 
cell count was aliquoted into an eppendorfvial for each sample. Samples were centrifuged at 
200X g for 5 minutes and the supernatant was discarded. For every 1x106 cells, 200 fll of 
PBS containing 50 flglml of RNAse A (# 84524822, Boehringer Mannheim, Germany) was 
added. Samples were incubated at 37°C for 15 minutes. For every 1x106 cells, 1 ml of PI (# 
P4170, Sigma, USA) staining solution was added to the PBS + RNAse solution, 20 minutes 
before F ACS analysis. Samples were analysed on a Facs calibur (Germany) using the cell 
Quest Pro. programme and data was exported and analysed using ModFit software. 
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2.7 Thioredoxin reductase activity 
Previous studies have shown that gold compounds inhibit Thioredoxin reductase activity in 
various cell types (See discussion and Figure in Chapter 1, Figure 11 ).111,121,122 To establish if 
the novel gold (I) compounds had the same mode of action, experiments were conducted to 
determine the effects of these compounds on the Thioredoxin Reductase system in 
oesophageal cancer cells. Auranofin, which has been shown to inhibit the activity of 
Thioredoxin Reductase in both the mitochondria and the cytoplasm, was used as a positive 
control. 75 
2.7.1 Extracting total Thioredoxin reductase (TrxR) protein 
This procedure was carried out essentially as described by Cox et al. (2008), with a few 
modifications. WHC01 cells (lx106) were plated in 100 mm plates and incubated overnight 
at 37°C. Cells were treated with 5 IlM of compounds 93 and 95, 6 IlM of compound 94 and 1 
IlM of auranofin (# EI-206-0/00, Enzo life sciences), for 30 minutes. Cells were then 
detached in trypsin, which was neutralised with medium. Cells were harvested and 
centrifuged at 200X g for 5 minutes. Samples were washed with lysis buffer and pelleted. 
The pellet was resuspended in 200 III of lysis buffer suplemented with 1 % (w/v) CHAPS (# 
220201, CalBioChem, Canada) and IX complete protease inhibitor (# 11697498001, Roche, 
Germany). Samples were then centrifuged at 10000X g at, 4°C, for 10 minutes. The 
supernatant was transferred into a clean eppendorf vial. 
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2.7.2 Fractionation assay 
This assay was conducted as described in Cox et af. (2008) with a few modifications. 
Because Thioredoxin Reductase is found both in the mitochondria and cytoplasm, a 
fractionation assay was conducted to separate mitochondrial and cytoplasmic extracts. 
WHC01 cells (12x106) were plated on 145 mm plates and incubated overnight at 37°C. The 
cells were treated with auranofin, compound 93, compound 94 and compound 95 as above, 
for 30 minutes. Cells were detached in trypsin, which was neutralised with DMEM. Cells 
were then harvested and centrifuged at 200X g for 5 minutes. The pellet was resuspended in 
1 xPBS and centrifuged at 600X g, 4°C for 5 minutes. The supernatant was removed and the 
pellet was frozen at -80°C for 10 minutes, to weaken the cell membrane. The pellet was then 
thawed and resuspended in mitochondrial isolation buffer supplemented with 150 J.1g1ml of 
digitonin (# D141, Sigma, USA) and IX complete protease inhibitor. Samples were 
incubated on ice for 10 minutes and then sonicated for 1 minute to ensure complete cell lysis. 
Samples were centrifuged at 1000X g, 4°C for 10 minutes to remove whole cells, nuclei and 
debris. The supernatant was transferred into a clean pre-chilled eppendorf and centrifuged at 
12000X g for 20 minutes. The supernatant (cytosolic fraction) was transferred into a clean 
eppendorf and the pellet (mitochondrial fraction) was resuspended in 200 J.11 of mitochondrial 
isolation buffer containing 2 % (w/v) CHAPS and IX Protease inhibitor. 
2.7.3 Thioredoxin reductase activity assay 
In the presence of Thioredoxin Reductase (TrxR) , 5,5' -dithiobis(2-nitrobenzoic) acid 
(DlNB) is reduced to 5-thio-2-nitrobenzoic acid (lNB); in an NADPH dependent 
reaction. I I I Using this principle, endogenous Thioredoxin Reductase activity was determined. 
The NADPH (# N6505, Sigma, USA) was dissolved in Phosphate EDTA (PE) buffer and the 
DlNB (# D8130, Sigma, USA) was dissolved in DMSO. The experiment was conducted in 
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duplicate. Protein sample (60 J-Lg) from either the total TrxR extraction or fractionation assay 
was mixed with 180 J-Ll of 0.24 mM NADPH and 6 J-Ll of 5 mM DTNB. The change in 
absorbance (at 5, 10, 20 and 60 minutes after the first reading) was measured at 405 run on 
the BioTek EL800 microplate reader using GenS software, and data was analysed using 
Microsoft excel. 
2.8 Protein quantification 
The Bicinchoninic Acid (BeA) assay is a commonly used assay in protein quantitation. In 
principle, the presence of protein results in the reduction of eu +2 to eu +, which further reacts 
with the BeA to give off an intense purple colour that can be measured at 562 - 595 nm 
wavelength. 123,124 The colour intensity is dependent on the amount of protein that is present 
and the incubation time. The BeA assay kit (# 23225, Pierce, Rockford, USA) was used to 
quantify the protein samples and a 2 mglml bovine serum albumin (BSA) stock was used to 
generate a dilution series ofBSA standards (2 mglml, 1.5 mglml, 1 mglml, 0.75 mglml, 0.5 
mglml, 0.2 mglml and 0.1 mglml), which were used to determine the protein concentration 
for unknown samples. The absorbance was measured at 595 run on the BioTek EL800 
microplate reader using GenS software. 
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2.9 Western blot analysis 
2.9.1 Antibodies 
Primary antibodies were purchased from Santa Cruz Biotechnology, Cell signaling (USA) 
and Sigma and all primary antibodies and incubation conditions that were used are shown in 
Table 2.4. The donkey anti-goat secondary antibody (# SC2020, Santa Cruz Biotechnology, 
USA), goat anti- rabbit (# 170-6515, BioRad, USA) and goat anti-mouse (# 170-6516, 
BioRad) HRP-conjugated secondary antibodies were used at dilutions of 1 :4000 in 2.5 % 
(v/v) milk, 1 :5000 in 5 % (v/v) milk and 1: 1000 in ms-Tween, respectively. 
Table 2.4: Primary antibody conditions used for Western blot analysis. Interleukin 8 
receptor beta (CXCR2P), Insulin-like growth factor -1 receptor beta (IGFIRP), Poly ADP-
ribose polymerase 112 (pARP), Peroxiredoxin (PRX), phospho-histone 2AX (yH2AX). 
Antibody (Ab) Catalog no. Company Dilution Diluent Type 
p-tubulin (h-235) SC9140 SantaCruz 1:1000 mS-Tween Polyclonal Biotechnology 
CXCR2P (s-16) SC22661 SantaCruz 1:2000 TBS-Tween Po lyclonal Biotechnology 
IGFIRp (c-20) SC713 SantaCruz 1:1000 5 % Milk Polyclonal Biotechnology 
P ARP (h-250) SC7150 SantaCruz 1:1000 5 % Milk Polyclonal Biotechnology 
PRXI SAB2101877 Sigma 1:1000 2 % Milk Polyclonal 
PRX2 SAB2101878 Sigma 1:1000 2 % Milk Polyclonal 
PRX3 AV52341 Sigma 1:2000 2 % Milk Polyclonal 
yH2AX (s-139) 2577S Cell signaling 1:2000 TBS -Tween Monoclonal 
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2.9.2 Protein extraction 
2.9.2.1 Protein extraction for P ARP and yH2AX deteCtion 
WHCOI cells (lxlOs) were plated in 60 mm plates and incubated at 37°C overnight. Cells 
were treated with compounds 93, 94 and 95 at IX or 2X the ICso concentration, for 12, 24 
and 48 hours. Doxorubicin (5 JlM) was used as a positive control. Proteins were extracted in 
60 Jll radioimmunoprecipitation assay (RIP A) buffer (recipe is in the appendix) supplemented 
with IX complete protease inhibitor cocktail and 1 mM Na3 V04 phosphatase inhibitor (# 
S6008, Sigma, USA). Cells were scraped off the dish using a cell scraper and the lysate was 
sonicated for 10 seconds. The cell lysate was centrifuged at 11000X g for 12 minutes at 4°C 
to remove cell debris and the supernatant was transferred into a clean eppendorf vial. The 
protein concentration was determined using the BCA kit and protein samples were stored at -
80°C. 
2.9.2.2 Protein extraction for IGFIR and CXCRl detection 
WHCOI cells, WHCOI IGFIR shRNA knockdown cells, WHCOI Ctrl shRNA cells, and 
WHCOI CXCR2 shRNA knockdown cells were cultured in 100 mm plates to about 80 % 
confluency. Proteins were extracted in 200 Jll of RIPA supplemented with IX complete 
protease inhibitor cocktail and 1 mM Na3 V04 phosphatase inhibitor. Protein samples were 
then processed as described above (2.8.2.1). 
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2.9.3 Sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein sample (5 ~g) was added to 5X Laemmli buffer for the detection of PARP and 
yH2AX, while 20 ~g of protein was used for the detection of IGFIR and CXCR2. Samples 
were denatured at 95°C for 5 minutes prior to loading. Protein samples were electrophoresed 
through a 4 % stacking gel and 10 % resolving gel. The voltage was set at 180 V and samples 
were electrophoresed for 1 hour. 
2.9.4 Immunoblotting 
Proteins were transferred onto a HybondTM-ECLTM nitrocellulose membrane (Amersham Life 
sciences, UK) at 4°C for I hour at 100 V. The transfer tank was kept on ice to maintain a cool 
environment. 
Membranes were blocked in 5 % (w/v) fat free powder milk (dissolved in TBS-Tween) for 1 
hour at room temperature on a shaker. The primary antibody was added and incubated 
overnight at 4°C on a shaker. 
Membranes were subjected to three 10 minute washes with TBS-Tween at room temperature 
on a shaker to remove unbound antibody. The secondary antibody was added and incubated 
for 1 hour at room temperature on a shaker. The 10 minute wash steps were repeated before 
detection. 
2.9.5 Immunodetection 
Super signal detection reagent (# 34080, Pierce, USA) was used to detect protein and in 
instances where the protein signal was too low, LumiGlo Reserve (# 54-71-00, KPL Inc, 
USA), which is a much more sensitive detection reagent was used, according to the 
manufacturers instructions. X-ray film was exposed to membrane with chemiluminescent 
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substrate for varying exposure times. The X-ray film was developed until bands were clearly 
visible before being fixed. 
2.9.6 Stripping the nitrocellulose membrane 
Because most of the primary antibodies used were produced in the same animal model, 
membranes were stripped using beta-mercaptoethanol stripping buffer. Unlike glycine 
stripping buffer which removes the secondary antibody only, beta-mercaptoethanol stripping 
buffer removes both primary and secondary antibodies. 125 Membranes were incubated with 
beta-mercaptoethanol stripping buffer (pre-heated to approximately 40°C) for 15 minutes at 
room temperature. Membranes were rinsed briefly in TBS-Tween and blocked with 5 % 
(w/v) fat free milk for 30 minutes at room temperature on a shaker. Membranes were then 
processed as previously described. 
2.9.7 Peroxiredoxin (Prx) Western blotting 
Prx is a ROS scavenger and a downstream target of Thioredoxin Reductase. Prx exists in 6 
different forms of which Prxl and 2 are specific to the cytoplasm and Prx3 is specific to the 
mitochondria. 126,127 To determine the downstream effects of TrxR inhibition, Prxl, 2 and 3 
protein levels were detected using non-reducing Western blot conditions, which are suitable 
for detecting both the oxidised and reduced forms of the Prx proteins. WHCO 1 cells (2x105) 
were plated in 60 mm plates and incubated overnight at 37°C. Cells were treated with 1 ~M, 
3 ~M and 6 ~M auranofin in DMEM for 30 minutes, 2 and 4 hours. DMEM was removed 
from the cells and 1 00 ~l of NEM (# 04259, Sigma, USA) buffer supplemented with 10 
~g/ml Catalase (# C1345, Sigma, USA) and IX Protease inhibitor was added to the cells. 
Plates were incubated at room temperature for 15 minutes. 1 00 ~l of 2 % (w/v) CHAPS was 
added to the plate containing NEM buffer and cells were scraped off the plates using a cell 
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scraper. To ensure efficient cell lysis, samples were further homogenised by pippeting up and 
down several times. Protein samples were quantified as described above and 20 J1g of protein 
was combined with beta-mercaptoethanol-free loading dye and electrophoresed on a 12 % 
SDS-PAGE gel. Proteins were transferred to a nitrocellulose membrane and blots were 
processed as described previously. 
2.10 ROS assay 
Elevated levels of ROS are indicative of cellular stress that may potentially lead to the 
inhibition of the cell cycle or induction of apoptosis (amongst other responses).128 The 
Thioredoxin reductase system is one of the major pathways involved in regulating ROS and 
effectively inhibiting the Thioredoxin reductase pathway will lead to an increase in ROS 
levels. To detennine the effects of compounds 93, 94 and 95 on ROS levels, a ROS assay was 
established, where Doxorubicin (# D1515, Sigma, USA) was used as a positive control. 128 
WHC01 cells (lx10s) were plated per well in 6 well plates and incubated overnight at 37°C. 
Medium was removed from the plates and the cells were washed with wann Kreb's Ringer 
(KR) buffer. Cells were incubated with 50 J1g/ml DCFDA (# D6883, Sigma, USA) at 37°C 
for 30 minutes. Cells were treated for 30 minutes with IX or 2X the 1Cso concentration, the 
drug was added directly to the DCFDA and KR buffer solution. Cells were harvested by 
trypsinisation in 1 ml of trypsin which was neutralised with 200 J1l of FCS. Wells were 
washed with 1 ml KR buffer and pooled with trypsinised cells. Cell extracts were centrifuged 
at 200X g for 5 minutes and the pellet was resuspended in 500 J1l of KR buffer. 100 J1l of 
sample was aliquoted into white (opaque) 96 well plates in triplicate. Fluorescence was read 
on a Cary Eclipse fluorescence plate reader at an excitation wavelength of 484 nm and 
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emission of 530 nm. The remaining 200 J.1l was used for protein quantitation. Data was 
normalised using the protein concentration. 
Because reproducibility was a problem with the above protocol, a second protocol was 
developed. 
WHCOI cells (2xI04) were plated in tissue culture white 96 well plates. The cells were 
incubated overnight at 37°C. Medium was removed from the cells and cells were washed in 
warm KR buffer. Cells were incubated with 50 J.1g1ml DCFDA for 30 minutes at 37°C. Cells 
were then treated with IX or 2X the ICso concentration for 30 minutes. Wells were washed 
twice with KR buffer and 100 J.1l of KR buffer was added to each well and plates were read 
on a Cary Eclipse fluorescence plate reader at an excitation wavelength of 484 nm and 
emission wavelength of 530 nm using the Advanced reads programme. Data was processed 
on Graphpad prism. 
2.11 ROS Scavenger assay 
To try and evaluate the effect of ROS levels on cell survival upon treatment with compounds 
93, 94 and 95, a ROS assay was conducted was conducted in the absence and presence of 
selected ROS scavengers. The crystal violet stain was used in this assay. The amount of dye 
that is taken up by the cells can be measured using a 96 well plate reader, upon addition of 
the solubilisation solution. 
WHCOI cells (5x103) were plated per well in 96 well plates and incubated overnight at 37°C. 
The experiment was done in triplicate. Medium was removed from the wells and the cells 
were treated with increasing concentrations (0.5, 3 and 5 mM) ofNAC in 90 J.1l DMEM for 1 
hour. 10 J.1l of lOX drug stock was added per well and incubated for 24 hours at 37°C. 
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Adherent cell were fixed in 100 III methanol per well for 10 minutes and stained with 40 III of 
crystal violet stain for 20 minutes. Cells were washed by immersing plates repeatedly in a 
basin containing tap water to reduce background. 100 III of solubilisation solution (50 % (v/v) 
acetic acid) was added to each well. After contents had been allowed to dissolve completely, 
the plates were read at 595 nm on the BioTek EL800 microplate reader using GenS software. 
Readings were exported as an Excel file and the data was analysed using Graphpad prism. 
2.12 Statistical analysis 
To evaluate the difference between treated and control samples, the t-test, one-way ANOV A 
(Dunnett) test as well as the Two-way ANOV A (Bonferroni) posttest, were conducted on 
Graphpad prism. The level of significance was set at p< 0.05. 
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Results Section 
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Chapter 3 
Screening novel compounds for cancer cell growth inhibitory properties 
3.1 Introduction 
In total 13 compounds consisting of 5 ligands, 5 platinum compounds and 3 gold (I) 
compounds were synthesised for this project, however the experiments to follow, were 
conducted on twelve compounds. Only re-crystalised and pure compounds were used in the 
assays described below. 
Cisplatin, 5-fluorouracil and doxorubicin, are chemotherapeutic agents that are currently used 
in the treatment of a variety of cancers including oesophageal cancer. 129,130 Because of the 
several side effects associated with the use of these drugs, there is an urgent need to develop 
novel chemotherapeutic agents, that are less toxic to normal cells, more specific to tumour 
cells and that induce their cytotoxic effects via mechanisms that are different from those of 
known chemotherapeutic agents. 
One of the objectives for this project was to determine the cytotoxic activity of the novel 
compounds previously synthesised in our laboratory (as described in Chapter 2.11) against a 
wide panel of oesophageal cancer cell lines, as well as some cervical and breast cancer cell 
lines, compared to normal fibroblasts. The effects of these compounds on cell function were 
determined using the MTT assay which is a standard assay used in the drug screening process 
during drug discovery, to assess cell proliferation and cytotoxicity.46,131-134 Other techniques 
such as flow cytometry for cell cycle analysis, as well as macroscopic observation of cell 
morphology by phase contrast microscopy and an evaluation of cell migration, using a 
scratch / wound assay, were also used during the drug screening process. There are several 
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studies that have highlighted the importance of developing novel chemotherapeutic agents 
targeted at inhibiting uncontrolled cell proliferation, angiogenesis, invasion, as well as drugs 
with an ability to promote apoptosis and reverse loss of cell differentiation. 80,\35, 136 Thus by 
conducting cell cycle analysis, cell morphology and cell migration assays we were able to 
determine the effects of the novel compounds on uncontrolled cell replication, cell 
differentiation and invasion, respectively, all of which are important markers of 
tumourigenicity . 
3.2 Effects of compounds on cell viability 
The indicated cells were treated with different concentrations of the compounds as indicated 
in Section 2.3.1 for 48 hours, and cell viability was determined. The results for the MTT 
assays (some typical results shown in Figure 3.1) were used to calculate ICso values for the 
various compounds in the cells tested. Compounds with ICso values above 100 J.1M were 
considered inactive, and these ICso values as well as those where the ICso could not be 
determined are reported as undefined (UD) in the tables. Although compounds with an ICso 
value less than 100 J.1M were considered active, this did not mean that their level of activity 
and selectivity were the same. For instance, compounds with ICso values of 10 J.1M or less 
were considered to be more active than those with ICso values of 15 J.1M and above. 
Suggesting that if an ICso value of 2 J.1M was obtained for cell line (a) after treatment with 
compound (x) and an ICso value of 10 J.1M was obtained in cell line (b), for the same 
compound. This meant that compound (x) was more active in cell line (a) when compared to 
(b) and thus more selective in cell line (b), suggesting that 10 J.1M of compound (x) would be 
toxic to cell line (a). Thus the results were interpreted with these considerations. 
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The platinum compounds were first tested on a panel of oesophageal cancer cell lines (Table 
3.1) and of the five platinum compounds tested, compound 84 showed the most activity 
against cancer cells, with an ICso value of 2 flM for the WHCOI cell line and 4 flM for the 
KYSE450 cell line. The rest of the compounds (85 to 88) showed little or no activity against 
the oesophageal cancer cell lines. 
The activity of these compounds was also tested on other cell lines which included two 
cervical cancer cell lines and two normal fibroblast cell cultures (Table 3.2). Compounds 85 
to 88 showed similar activity to that observed in the oesophageal cancer cell lines. Compound 
84 showed slight selectivity in the FOo cells. 
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Figure 3.1: MTT results obtained after treating cells with platinum compounds. The 
above MIT results are a general representation of the observations made after treating 
various cell lines with platinum compounds. The data points represent the mean of the 
triplicate and the error bars represent the SEM. Cells were plated in 96 well plates and 
cultured for 24 hours. Thereafter 10 J.11 of medium containing various concentrations of 
compounds were added to the wells and incubated for 48 hours. The final DMSO 
concentration in all the wells was 0.2 %. After 48 hours, MIT reagent was added and 
incubated for 4 hour, followed by solubilisation reagent. After 16 hours, the absorbance of 
the plates was determined at 595 nm and the ICso values were calculated as described in 
materials and methods. ICso values that were less than 100 J.1M as represented by A, B, C and 
E were considered active, and those that were above 100 J.1M (0) or in instances where a 
graph could not be obtained (F) were considered inactive and are presented as undefined 
(UD) on the results tables. 
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Tabld.1 
Testing the effects of platinum c"mpound~ on cell ,iability 
Five platillUDl comp<JUllds were tested for tkir effects on cell viability by comluctillg MIT 
assays on fivc oc'lqlhageaJ canc~r edl lines, Drug 84 Wa" not tested on the cell li ncs 
indicated by a dash (-). IC,o values that were above 100 ,..M or ill illstaUC~s where a graph 
could not be obtained the result, are expressed as undefined (UD). Thi, r~sult represents a 
single expc-nment oone in triplicate and data ~l1aly"is was done On graphpad. 
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Table 3.2 
Testing the effl'ds of platinum eorupound~ on cell viabil ity 
Five platinum compounds were tested for tkir effects on cell viability by conducting :\ITT 
assays on cervical cancer cell lines and nOimal fibroblast cultures, Drug 84 was not tcsted on 
the c~II lin~ indicated by a da"h (-) . IC", valuc, Ihm were above 100 "M or in in.,tance" 
wher~ a graph coLIid not be obtained the rcsults are expressed as undetincd (UD). This result 
represents a ,ingle experimetlt done in triplicate and data analysis was oon~ on graphpad. 
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for cancer therapy because other metal-based compounds may show reduced side-effects, and 
yet still display significant anticancer activity. Consequently, the PhD student in our 
laboratory had ligated all the ligands to Chlorotetrahydrothiophen [Au(tht)Cl] as shown in the 
materials and methods (section 2.11), but only compounds 93 and 94 were soluble 
(representing ligands 63 and 64) and could be tested further. In addition, compound 95 was 
synthesised by reacting Au(tht)Cl with triphenylphosphine. All three compounds were then 
tested for anticancer activity. The general overview of the MIT results obtained after 
treating cells with gold (I) compounds are presented in Figure 3.2. 
The presence of a gold metal atom instead of a platinum metal generally appeared to enhance 
the activity of the compounds. ICso values of 12 to 16 f.1M were obtained in the KYSE4lO 
and KYSE450 cell lines (Table 3.3) which showed little or no sensitivity to the platinum 
compounds (Table 3.1). The gold (I) compounds showed the most activity in the WHCOI 
and KYSE150 cell lines and the least activity in the KYSE70 cell line (Table 3.3). To 
determine if the gold compounds were active in other cancer types, MIT assays were 
conducted on cervical and breast cancer cell lines as well as on normal fibroblast cell cultures 
(Table 3.4). 
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Figure 3.2: MTT results obtained after treating cells with gold (I) compounds. The data 
points represent the mean of the triplicate and the error bars represent the SEM. Cells were 
plated in 96 well plates and cultured for 24 hours. Thereafter 10 f.Ll of medium containing 
various concentrations of compounds were added to the wells and incubated for 48 hours. 
The final DMSO concentration in all the wells was 0.2 %. After 48 hours, MTT reagent was 
added and incubated for 4 hour, followed by solubilisation reagent. After 16 hours, the 
absorbance of the plates was determined at 595 nm and the ICso values were calculated as 
described in materials and methods. The gold compounds were observed to be generally 
active across all cell lines tested. 
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Table 3.3 
Testing tile effects of gold (1) comp{mnds on cell viability 
Three gold compounds were tested for their effects on cell viabil ity by condLicting MTT 
assays on oesophageal cancer cell li nes. The 95 % conlidence interval (el) ~oukl not be 
obtained in the samples designated by a dash (·).11ris result represents a single experiment 
done in triplicate and data analysis was done on graphpad. 
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Teuing the effects of gold (1) compounds on cell 'iabilit)' 
Three gold compounds were tested for their clfeclS On cell viability by cooducting MIT 
assays on three cervical cancer cell lines, two breast cancer and two normal ti.broblasl 
cultures. This result represents a single experiment done in tripli~ate and data illlalysis " 3S 
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The gold (I) ~hloride compounds were effective against all the cancer cell lines tested but 
were ~imilarly active in killing !lonnal cells (Tahle 3.4). The CaSki cell line which showed 
the least >ensiti vity to t.-.,atment with platinum compounds wa~ one of the most responsive 
cell lines to the treatment with gold (I) compounds. The non-scledivity or lOC gold (I) 
compounds against the cancer cells compllrcd to normal fibroblasts is disappointing, but 
consistent Wilh the response of \'iIICO I, FGa and VMB cells w treatment with known 
ck'1llothcrapeutie agents (Table J.5). Allhough the novel compounds silO\\' no ,elcctivily. it 
may be beneficial to further explore the~e finding~ OIl animal models. 
Table 3.5 
Testing the effects of known cJlemotherapeutic drugs on cell 'iability 
Three knOW!l chemotherap<:utic agenlS were tested ror their e/lccts on cell ~iability by 
conducting MIT a~sa)'S OIl the o<:sophagNI cancer cell line, WHCOI and two nonnal 
fibrobla~ts Fa., and VMB cultures. The 95 % confKien~e interval (Cl) could not be obtained 
in the samples designated by a da,h (-). To ,how reproducibility the results obtained from the 
firnt experiment and the repeat experiments are preo;ented on this table Data analysis was 
done on graphpad. 
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Although highly active in killing cancer cells, doxorubicin appeared to be more effective in 
killing the DMB cells, but showed little activity against the FGo cells. Similar to the novel 
gold (I) compounds, 5-fluorouracil showed no selectivity in killing normal and cancer cells. 
In order to evaluate how the presence of the metal atom contributes to drug activity, MIT 
assays were conducted on the uncomplexed ligands (compounds 60 - 64). The ligand for 
compound 85 was excluded because it was insoluble in the medium. The general overview of 
the MIT results obtained after treating cells with ligands is presented on Figure 3.3. Ligands 
with ICso values similar to the ones observed in A and C were considered inactive because 
the ICso values did not correspond to the observations made on the graph and in same cases 
the 95 % confidence interval (CI) could not be obtained (Figure 3.3). However ligands with 
ICso values similar to the ones shown in B and D were considered active. 
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Figure 3.3: MTT results obtained after treating cells with ligands. The data points 
represent the mean of the triplicate and the error bars represent the SEM. Cells were plated in 
96 well plates and cultured for 24 hours. Thereafter 10 III of medium containing various 
concentrations of compounds were added to the wells and incubated for 48 hours. The final 
DMSO concentration in all the wells was 0.2 %. After 48 hours, MIT reagent was added and 
incubated for 4 hour, followed by solubilisation reagent. After 16 hours, the absorbance of 
the plates was determined at 595 nm and the ICso values were calculated as described in 
materials and methods. 
Generally the ligands appeared to be slightly more active on their own than when complexed 
to a platinum metal atom (Table 3.6), particularly in the WHCOI, WHC05 and KYSEI50 
cell lines. However, ligand 60 which showed the most activity when complexed to a platinum 
metal (compound 84) showed the least activity in the absence of the platinum metal atom. 
The ligands appeared to be less active on their own compared to when they were complexed 
to a gold metal atom, suggesting that the presence of a gold metal instead of a platinum metal 
enhanced their activity. Similar observations were made when the ligands were tested on the 
cervical cancer cell lines and normal fibroblast cells (Figure 3.7). 
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Tahlt 3.6 
Ttsting tht tfTectli of ligands on cdl viabmt~, 
Four ligands were tested [or their efT""ts on cell viability by C<lnducting MTT assays on 
oeS<Jphageal cancer cell lines, Ie", values that showed ambiguity as seen on Table 3.3 or 
t1K,SC that were above 100 I'M are expressal as undefined (UDl_ This ,,"suIt represents a 
single experiment done in triplicate and data analysis was oone OIl grapbpad, 
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The MTT assays were only earried out once for the platinum com]XlUnds but hecau"" the 
expcriment was conducted on a wide range of cell liIltlS and the results obtained were 
consistent a<-TllSS all the different cell lines. it was safe to conclude that the platinum 
C<lmpounds werc inactive. The gold compounds showed significant amounts of activity and 
the ligands displayed varying activity ranging from being slightly active to showing no 
activity, Furthermore the activity displayed by the gold compounds seemed to be ligand 
independent as compound 95. which lacked the ligand backbolle, waS observed to have 
simi lar activity to COlll]Xlunds 93 and 94. 
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Tablt' 3.7 
Tt'Hing tht' t'1Tt'cts of lig9nd~ on cell "iability 
Four ligand~ were tested for their effect~ on ceJl viability by conducting MTT assays on 
~ervi~al ~an~cr ~eJlli nes and normal fibroblast cultures. Ie", values that showed ambigllity as 
indi~ated on Table 3.3 Or tho~e that were aoove 100 ].1M are expressed as undefined (UD). 
Thi~ result represents a single experiment done in triplicate and data analys:i~ was done on 
graphpad. 
.. 
" 
" M LID 
To ~oofinn the activity observed for the gold compounds and the ligands. MTI assays were 
repeated on the three gold ~ompounds and On ligands 63 and 64, which are specific to 
~ompound 93 <md 94, respe~li vely. Even lhough the compounds do not show selectivity in 
killing cancer cell~. it i~ still important to characterise compounds that may have a mode of 
",,[ion diITt;relll Ii-om that of ~isplatin and other compounds that have been assoc iated with 
multiple side eilects. For this reason further experiments were conducted on the gold (I) 
chloride compounds, which ~howed the mo~t activity, against a broad range of cells. The 
experiments that follow were conducted using concentrati(m, ohtain~d afr~ r avcraging ((\0 
values from the first and ~econd experiments conducted (m tl-.e go ld (I) compllunds, whet'e the 
mean value for compound 93 was 5 ].1M, compound 94 was 6 ].1M and 5 ).1M was obtained I'll] 
oompound 95. 
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J.J The effect~ of gold (I) chloridc compouud, ou ull morphology 
From the p" evious MTI assays it was established that the gold compounds affect cell 
viabilily. It was thus interesting to determine whether the effect. were a,,"ociated with any 
obvious morphological changes_ \,VIlCOI cell" were tr~ate d with the indicated compound, at 
IX and 2X the /C.o conc~ntrations (,,"",an of lC,o values obtained from two independent 
MTT experiments) for 12, 24 and 48 hours and lh ~ c~lI morphology was obser>ed at each 
lime point (figure 3.4). DMSO treat~d cel l, were used as a negative control and doxorubicin 
(dox) lmated cells were used as a positiv~ control (Ctrl). 
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Figure 3.4: Effects of "'<Impounds on cell 
mO'l,hology. "WHC01 cell, were trealed 
with 1 X and 2 X the IC", concentrations of 
compound, 93.94 and 9S for 12,24 and 48 
hour5. and t~ cell morphology was observed 
under the phase conlrast microscope. Toc 
controls are shown in the top panel for all 
three lime points, where DMSO trealed cells 
(left) were u,ed as a ncgmiH conlrol and 
doxo",bicin lrealed cells (right) were used as 
a f'O,itive comro!' The bottom panels 
repreM:nlS cells treated with IX and 2X the 
Ie"" c.oncentralion for compounds 93, 94 and 
95, al each lime point. The black arrows 
indicale obs<:rved morphological changes. 
Thi, ""ul1 i, representative of 3 independent 
experimems. The piclUres were taken at 
12%x972 reso lutions. 
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After 12 hours of treatment the cells treated with doxorubicin appeared more rounded when 
compared to DMSO treated cells, similar observations were made for the cells treated with 
compounds 93, 94 and 95 at IX and 2X the ICso concentration. In addition to this a decrease 
in cell number was observed for the cells treated with the indicated compounds when 
compared to DMSO treated cells (consistent with the MTT results). Cell clumping was 
observed for the positive control and the cells treated with 10 ~M (2X the ICso concentration) 
of compound 95 at 24 hours. A decrease in cell number was observed for all gold (I) treated 
cells accept for the cells treated with IX the ICso concentration (6 ~M) of compound 94. 
Similar to the earlier time points a decrease in cell number was observed for the higher 
concentrations for all gold (I) compounds and the positive control at 48 hours. 
In conclusion, treating cells with compounds 93, 94 and 95 led to a decrease in cell number, 
particularly in the cells treated with the higher concentrations, when compared to DMSO 
treated cells, for all time points. 
3.4 Time course of effects of compounds on cell viability 
One of the hallmarks of cancer as reviewed by Hanahan et al. (2000) is the ability of cancer 
cells to evade anti-growth signals and to provide their own growth signals.82 This 
uncontrolled growth of cancer cells is also associated with the invasion of the basement 
membrane and the spread of the cancer to other tissues via the lymph and blood. Therefore 
the ability to limit cell proliferation is essential in preventing tumour growth. 
Since in the previous section we had shown that the gold (I) compounds were capable of 
reducing cell number, here we wanted to determine the time course of the effect of these 
compounds. MTT assays were conducted and the effects of compounds on cell proliferation 
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were monitored over a period of five days. Compounds 93, 94 and 95 appeared to inhibit cell 
growth in a time and dose dependent manncr (Figure 3.5). Cell growth inhibition wa, 
observed 24 hours after treating cells with compounds 93 (10 ~M) and 94 (12 J-lM) and lhi, 
inhibition was maintained for more than 72 hours. CompoWJd 95 (10 ~M) appeared to have 
n()ti~~"ble e ITeel on cell growth inhihitio[! 72 hours after treallnent. 
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Hl(urc 3.5: Cell growth lIS~ay. WHCOl cell, were treated with 0.5, lX and 2X the le,o 
concentration as described in the materials and methods beforc adding MIT and solubilising 
reagent. These results represent 3 independent experiments conducted in triplicate and the 
error bars denote the standard deviation (SD), 
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As it has been mentioned previously, the cell cycle plays an important role in regulating cell 
growth and part of the screening process during drug discovery involves looking at the effects 
of novel compounds on cell proliferation. Thus the observations made from the growth assays 
directed us to investigate the effect of these compounds on the cell cycle. 
3.5 Effects of gold (I) chloride compounds on the cell cycle profile 
The cell cycle, which is the core machinery for regulating cell proliferation, exhibits 
checkpoints that amongst other processes monitor DNA integrity, an essential step that 
identifies DNA mutations and ensures accurate DNA duplication during synthesis. 116 As 
mentioned above, tumour cells have an ability to evade anti-growth signals and this is 
commonly associated with defective cell cycle check points. To assess the effects of our 
compounds on the cell cycle profile, WHCOI cells were treated with the various compounds 
for 12, 24 and 48 hours and the cell cycle was monitored. During this experiment doxorubicin 
was used as a positive control. An example of a typical cell cycle profile obtained after 
treating WHCOI cells with the gold compounds is presented in Figure 3.6. However, all the 
data obtained at each time point was transformed into histograms to facilitate analysis (Figure 
3.7). 
An increase in the S phase was observed 12 hours after treatment with all three compounds, 
compared to the DMSO treated cells (Figure 3.7). The same observations were made at 24 
and 48 hours, suggesting a time- and dose-dependent inhibition of the cell cycle. These 
observations were supported by the statistical data shown in Table 3.8, where a student t-test 
was used to determine the statistical significance of the S phase arrest for the different 
treatments, by comparing DMSO treated cells to cells treated with compound. 
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figure 3.6: Cell cycle profile for gold (I) compounds. This data represents an overview of 
the results obtained after treating WHeOI cells with gold (I) compollnds. hlO' WHeOI 
cel], were plated and incubated overnight at 3rc. The cells w~r~ treated with IX and 2X rlle 
1C5<) concentration for 12, 24 and 48 hours. Celh were harvested at the indicated time jXlints 
by trypsinisation and tt.. samp k. were proces>ed a, de_<cribed in materials and methods. 
Samples were analysed on a Facs calibur using the cell Quest Pro. programme. 
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Flg1ll'f 3.7: Cban~n: obn1'\ 'ed In Ih~ ""I] "yde profile .ft~,· t~eatinil ~elh; wi tb Ih ~ ~()j d (I) 
ro1ll1XlUm1 1l . WI!COI .. cl "~ " 'cre I~alt:d with IX and 2 X the lC,o OOIlCC!ltnltjU!l~ for 12. 24 
and 4S h .... \nI . Ch!lll';_-s in the cell cycle were determined by fl",,· cytumetry. Mean w l",;s ar~ 
sho:lwn un Ihe l~blc;s below the graph., Tn.,.~ resu lt. arc rq1rcscnlali\'c uf 3 ind'-ll"ndent 
l""perimcn\~ oonciuCle,\ in triphca.tc. The error bar. denote t f>e SO. 
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Table 3.8 
Slatisticaillnalysis for cell cycle profile results 
Statistical analysis was done OIl the percentage of ceUs in the S phase only, where DMSO 
treated cells were compared to cells treated with doxorubicin and the gold (I) compounds for 
12. 24 and 48 hours. These results are representative of three indepcndcm experiments 
conducted in triplicate and the replicates for each treatment coudition were used (0 cakulale 
the p-values using the student t-test (Resul ts obtained from the other two experiments are 
shown On Tables 5 and 6 in the appeudi~ A). The mean and standard deviation (Stdev) for 
each lreatment point are also included in the table. * indicates significance p<0.05 
M.ti.tk.l .n.ly,h (TTfST) 
.. . I .. . j In Nh "" ~J •• n ,. S,d.-' p_"ah" '>I •• u , Sf"", p~;~,,~- -· M .. o , 
-
D\lS0 39.9 
" 
413 
., 
22 I " f 0 ,0124]2' )4,:' 
~_ SI<\..,. .. ' p_n l"" 
u :.:j 
5 ~'l OOX 49.:- 0.4 OJXl442,' J.6,8 I." 48." 3. 1) 0.(){)(,9:-0' 
5 ~\l <)J 456 , n,',.' '.i, • ~}.~ U 0.021125' 3.14 r_?1 i 0.00%%-
to 1''' Q3 \ 0 , U O.OI ::04Y' "'., U i 0.001 754' 471 • t ~" ouoo:m' 
-6 ,,"1 9~ "'.6 00 0.006tW' 52.0 0.3 0.015:-57- }iLL 1.) O-'i t4m I ' , 
"' 4\,4 'r= 01' . lZ I,~t ')4 5(, OJ U.U ():.'38~ · J.6.3 3 ,1 U UU5217-
o.or"2'9* 1 
-
. 
, 
S IIl\] 95 M.~ I.J U,U?I%6' ~H + .. .0 7 ~ 00Pil5' W.l 00 0.0'7.11)4' 48 ,2 0.' %.2 • 0.iKISR54* , :\5.3 0. 1 , 
.-!O 1''' 95 0.1114111' 0.7 U.UU0754-
A significant inhibition (. p< 0.05) of the cell cycle at the S phase was observed 12 hours 
after treatment with the gold (I) compounds, except in the cells m.ated with compound 93 
(5IJ.M) (Table 3,8) The data obtained at the 24 and 48 hour time [X>iuts was statistically 
different from the DMSO treated cells (* p< 0.05). and this was consistent with the 
observations made in Figure 3.7. Un
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3.6 Effeds of the gold (I) compounds on cell migration 
Since we had already monitored the effects of these compounds on cell viability and the cell 
cycle profile, we also wanted to determine if these compounds had an effect on cell 
migration, another important characteristic of tumorigenesis. WHeOI cells were treated with 
compound as described in the materials and methods and the scratch width was measured at 
0, 8 and 24 hours after treatment. The cells were treated with Mitomycin e (MM), an 
inhibitor of cell proliferation, to ensure that the decrease in scratch width was due to 
migrating cells and not proliferating cells. At time 0 (Figure 3.8, first panel from the left) it 
was observed that the scratch widths were approximately the same size. 8 hour after 
treatment, the scratch width had decreased by ±40 % in the cells treated with DMSO, 
Mitomycin e, compound 93 and compound 94, where as only a ±20 % decrease was 
observed in the cells treated with compound 95. At 24 hours, the scratch width for the DMSO 
treated cells had come to almost a complete close and the MM treated cell remained more or 
less in the same position as observed at 8 hours. A further 10 % decrease in the scratch width 
was observed for the cells treated with compound 93, while a ±5 % increase in the scratch 
width was observed for compound 94 and a similar but opposite effect was observed for 
compound 95. 
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Fi!<:u rc 3.8: Cdl m;grutiun "ssay. 
WlleO] cells were treated with 
DMSO only or 10 !lg/ml of 
Milomycin C (MM) along with 
eilher 5 ~M of compound 93 or 95 
and 6 ~M of compound 94. CAl Tht. 
scratch width was measured at O. 8 
and 24 hours after treatment. (B) 
The results were quantitated by 
plotting nonnaiised daw on ll~ 
graph. This resu lt is representative 
of 3 independent experiments. lwo_way ANOV A analysis was performed using Bonferroni 
postle"!, which compared all [realed cdls to MM treated cells at ~ach tim~ point. p < 0.0001 
("'),0.001< P <0.0] (**), O.Ol<p<O.05 CO). 
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3.7 Discussion 
Twelve compounds were synthesised in our laboratory and were tested for anticancer 
activity. These compounds were grouped into four categories which are shown in the 
schematic diagram below (Figure 3.9). From the cell viability assays, most of the platinum 
complexes (85, 86, 87 and 88) were inactive against most of the cell lines tested, as well as 
the fibroblast controls. However, compound 84 appeared to have activity against the cancer 
cells but was slightly less active against normal fibroblast, suggesting that it would be useful 
to carryout further investigations on this compound in the future. The gold complexes seemed 
to be much more active than the platinum complexes and the free ligands, with the order of 
activity being gold complexes, free ligands and then the platinum complexes, suggesting that 
the presence of the gold metal atom may contribute to the activity of the complexes. These 
findings are consistent with the reports in literature. Where cytotoxic and 
immunoenhancement studies have been conducted on gold complexes and their ligands and it 
was observed that the gold complexes were more active than their ligands which showed little 
or no activity.139,140 A study which was conducted by Marzano et al. (2007) compared the 
activity of two known chemotherapeutic agents, auranofin, a gold (I) compound and cisplatin, 
which is a platinum (II) compound. In this study the two compounds were tested on a 
cisplatin sensitive cell line (2008) and a cisplatin resistant cell line (C13*) and auranofin was 
found to be highly effective, where ICso values less than 1.5 JlM were obtained for both cell 
lines. An ICso value of 6.5 JlM was obtained for cisplatin in the 2008 cell line and 114.8 JlM 
was obtained for the C13* cell line. 122 In addition, another study which compared the activity 
of gold complexes to cisplatin as well as to Tin and Silver complexes, indicated that the gold 
compounds were more active than cisplatin, and less active when compared to some tin 
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complexes; however they where found to share the same level of activity with the silver 
complexes.78 
All three gold complexes (93, 94 and 95) displayed similar high levels of activity against 
most of the cell lines tested. This suggested that the chemical and the structural nature of the 
ligand had very little impact on the activity of the gold complex. 
Using WHCO 1 cells as our model system, we were able to show that the gold (I) compounds 
(compound 93, 94 and 95) inhibit cell proliferation in a time- and dose-dependent manner 
(Figure 3.5). However, the gold (I) chloride compounds were found to be equally active 
against normal cells, a quality indicative of a certain level of general toxicity. In an article by 
El-sayyad et al. (2009), in vivo studies were conducted on cisplatin, doxorubicin and 5-
fluorouracil, where all three compounds were found to contribute to skeletal muscle and 
adipose tissue depletion, suggesting that toxicity is a common thread amongst anticancer 
therapeutic agents. 129 
Although the gold complexes significantly blocked cell proliferation in a wide panel of cells, 
they had no apparent effect on cell migration as measured in the wound healing assay. 
However, compound 95 on the other hand, significantly reduced cell migration (Figure 3.8). 
Although not shown in gold (I) compounds, there is evidence in the literature to suggest that 
gold compounds (specifically gold (III) compounds) inhibit cell migration.45 
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Figure 3.<;1: A simplistic carloon of the twelve compound. thai were le.ted for anticancer 
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A dose dependent 8 phase arrest was observed 12, 24 and 48 hours after treatment for all 
three gold (I) compounds, where an increase in the number of cells in the 8 phase correlated 
with a decrease in the number of cells in Gl (Figure 3.7). A review article by M. D. Garrett 
(2001), suggested that cell cycle arrest at the G 118 transition is caused by the presence of 
double strand breaks (D8Bs) in the DNA double helix and the cell cycle arrests at this point 
to prevent damaged cells from entering into 8 phase.141 Normally, when DNA damage is 
detected by the cell cycle checkpoints, the cell cycle arrests to allow the damaged DNA to be 
repaired, and if the DNA can not be repaired then apoptosis is initiated. However reports in 
the literature indicate that when DNA damage is detected at the 8 phase checkpoint the cell 
cycle does not arrest but instead DNA replication is slowed down. 141 Based on this evidence 
we may consider the possibility that treating cells with our compounds may cause DNA 
damage that is detectable at the G 1 checkpoint causing a G 1 cell cycle arrest. This 
speculation correlates with the observations made in Figure 3.7 at the 48h time point, where 
less cells were observed in the 8 phase and an increase in cell number at G 1, suggesting a G 1 
cell cycle arrest. Thus, to verify these speCUlations the presence of DNA damage should be 
determined. 
In summary, based on the observations made in the cell viability assays and the cell cycle 
profile, compounds 93, 94 and 95 seem to possess cytostatic effects that are both time and 
concentration dependent. 
To further establish the anticancer properties for the gold (I) chloride complexes, experiments 
to identify the molecular mechanism of action for these compounds, were conducted. 
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Chapter 4 
Effect of gold (I) complexes on selected biological processes 
4.1 Introduction 
In their review article, Lord and Ashworth (2010) indicated that understanding normal cell 
function has been a vital tool in the attempt to dismantle the biological defects that lead to 
tumour development. 142 Furthermore this has led to the identification of several mechanisms 
that are used by chemotherapeutic agents to inhibit cell proliferation and induce cell 
death. 142.143 
In the previous section, we had demonstrated that the novel gold (I) complexes (93, 94 and 
95) display significant activity against a broad panel of oesophageal cancer cell lines, as well 
as in the few breast and cervical cancer cell lines tested. Considering the substantial increase 
in activity of the ligands observed subsequent to complexation with gold, and not platinum, 
we designed a series of experiments to explore how the gold complexes prevented cancer cell 
proliferation. 
We determined the effect of the gold compounds on: DNA damage (using the phosphorylated 
H2AX as a marker of DNA damage), induction of apoptosis (by monitoring the cleavage of 
p ARP as a marker of apoptosis), redox systems (by monitoring the thioredoxin reductase 
system), and on ROS levels (by measuring ROS levels inside cells using a probe sensitive to 
ROS levels). 
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4.2 Dde~mining the levels of phosphor:yluted H2AX ufter treatment wi th gold (I) 
chloride compounds 
In the literature. therc is e"idenee to suggc,l timt some metal wmplexes block the growth of 
~an~er ce ll,. in part by cau,ing DNA damage."·"·' To assay for DNA damage. 
phosphorylated H2AX (yH2AX), an indicator of DNA damage, was dete ~te d bj' Western blot 
analy,i,. Doxorubicin and D.\1S0 treated , ells were used as po,ilive and ncgalive controls, 
resp.,.,liveiy. 
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Figure 4.1: Ildecting lewIs of phosphorylated H2AX uft,,!" treu tment with gold (Il 
compounds. yH2AX levels were detected by We,lcrn bIOI analysi, at J2 and 24 after treating 
the ,ells with IX and 2 X thc lC, " concentrations. Doxorubi~in (dox) anti the DMSO treated 
cells were used as po,itive and ncgative contrn ls, resp e~"tive ly. Thi, re,ult is rcpresentative of 
three independenl expcriments. 
From Figure 4.1, il appearcd as though for the 12 flour time point, phosphorylated H2AX 
levels werC only indu,ed by ,ompound 93 and 95 at 10 ].I"'!. Ilowever the ~-tubulin le"eis 
indicated that there was uneven lo>!ding. Ilut "ilen wmparing ~-lubu l in levels in the DMSO 
treated ~e lls 10 that in thc cells treated with compound 93 and 95 (10 .u.\11, the DMSO treated 
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cells were observed to have higher levels of p-tubulin. This observation suggested that the 
intense bands which were observed for compounds 93 and 95 (10 J-LM), were a true 
representation of the levels of phosphorylated H2AX, as low levels of yH2AX were detected 
in the DMSO treated cells. When comparing the p-tubulin levels of DMSO treated cells to 
those of doxorubicin and compound 94 (6 J-LM), it was evident that the uneven loading may 
have influenced the outcome of the observation made at these treatment points as low levels 
of yH2AX seemed to correlate with low levels of p-tubulin and the opposite was true. 
In contrast, treatment of cells with the gold (I) compounds for 24 hours resulted in a 
noticeable increase in H2AX phosphorylation, particularly at the higher concentrations of the 
compounds. A slight increase in yH2AX was observed for the cells treated with 5 J-LM of 
compound 93 and 95 when compared to DMSO treated cells. The p-tubulin levels at this time 
point seemed even in the cells treated with gold (I) compounds. However higher levels of p-
tubulin were observed in the DMSO treated cells, but this did not seem influence the levels of 
yH2AX. 
In summary, the induction of phosphorylated H2AX levels after treatment with gold (I) 
chloride compounds appeared to be time and concentration dependent. However, further 
experimentation is required for reproducibility and to solidify the current data. 
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4.3 Assessing levels of cleaved P ARP after treatment with gold (I) chloride compounds 
The data in Fig. 4.1 suggests that the gold (I) complexes do induce DNA damage within 24 
hours of treatment. Under normal circumstances, if the damaged DNA can not be repaired, 
the cells are forced into apoptosis.41,141 To determine if treatment with the gold (I) 
compounds drives the cells to undergo programmed cell death, levels of cleaved PARP were 
detected by Western blot analysis. P ARP is a nuclear protein that is involved in DNA repair 
and during apoptosis, P ARP is cleaved by caspases 3.104,105,145,146 Doxorubicin treated cells 
were used as a positive control and the DMSO treated cells were used as a negative control. 
At the 12 hour treatment point, a faint band corresponding to cleaved PARP was only 
detected in the positive control (Figure 4.2). Although the loading was uneven at the 12 hour 
point based on the intensity of the tubulin bands, this same trend was observed 24 hours after 
treatment. Cleaved P ARP corresponds to 89 kDa, and not the strong band observed at 
approximately 95 kDa in lane 2 at the 12 hour treatment point. At 24 hours, cleaved P ARP 
was detected at the higher concentrations of 93 and 95, with a very faint band observed for 
compound 94. An increase in the levels of cleaved PARP were observed at 48 hour in all the 
treated cells, except in the cells treated withl0 J.1M of compound 93, where the cells could be 
at a later stage of apoptosis. The results observed suggested that the compounds tested 
induced apoptosis. 
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Figure 4.2: PARP detection after treatment with I!old (1) compounds. WIICOI cdls were 
treated as dc><:riixd in materials and meth[)d" Doxorubicin (do:<) and DMSO tr~ated cells 
were used a, ~nntrol>. Unclcaved PAf{1' is 116 klla ami dca,'cd PARP is 89 kDa. This is 
representative of three ind~JX'ndent ~)Cperiments. 
The process of apoptosis may be triggered through the activation of several pathways, which 
include the mitochondrial pathway Or ,. ia the activation of the death receptor, (TNFR).94 
Caruso er at. (2001) reported that the plmsphil1" g[)ld (I) ~ompuunds induce apop<osis. 
primarily through targeting the milochondria of cells_ m However, other studies ha,·c 
identified auranufin, a gold (I) phosphine drug, as an inhibitor of Thiorecioxin Reductase 
activity in both the mitochondria and th~ cytoplasm_ L22.148.149 
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4.4 Determining Thioredoxin Reductase (TrxR) activity in response to treatment with 
novel gold (I) chloride compounds 
The Thioredoxin Reductase system is one of the most important pathways used by cells to 
regulate their redox status, and this process is NADPH dependent. As shown before (Figure 
11), NADPH reduces Thioredoxin Reductase (TrxR), which in turn reduces Thioredoxin 
(Trx), which then reduces Peroxiredoxin (prx), which serves as the proximal ROS 
scavenger.7S,147,148,ISO Because compounds 93, 94 and 95 are gold (I) compounds, we thus 
wanted to determine if, like auranofin, these compounds affect the Thioredoxin Reductase 
system. Based on the experimental procedures published in most papers, the absorbance for 
the TrxR assay is most commonly measured at 412 nm and with a few exceptions at 405 
nm.122,138,139,148,ISI,IS2 Since the option to measure absorbance at 412 nm was unavailable on 
our plate reader, but 405 nm was, an assay was conducted to measure the absorbance 
spectrum of the TrxR assay product across a broad range of wavelengths. No dramatic 
change in the 00 readings was observed between these two wavelengths when we compared 
the effects of compound 94 on absorbance in the sample treated with compound 94 in the 
presence and absence ofNADPH (Figure 4.3). Therefore the 405 nm wavelength was used to 
measure the absorbance for the TrxR activity assays. 
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Figure 4.3: Absorb'lnce readin\: olltimisalion experiment. 1bree test tubes were prepared 
for the Thioredoxin R~ductase assay as described in the materials and methods section. Tube 
I (black line) had D'vISO trented protein =tmct plus DTNB and NADPH, rube 2 (bllle line) 
contained a protein extract treated with compound 94 plus DTNB, minu~ NADPH and tube 3 
(red line) protein extract \\as treated with compound 94 and contained DTNB and NADPH . 
Each sample waS aiiqooted into a 0.5 ,"I cuvette and the change in ahsorbance at different 
wavelengths was measllred usiug the LN spectrophotometer. The green vertical lines indicate 
the 405 and 412 wavelength p<Jsitions and the green horuontal lines mark the 00 values 
obser,·ed at those \\ avelengths. 
Annmofin was used as a positive control for the TrxR assay and before the experiment, an 
'>iTT assay was ~onducted to determine the appropriate concentration of auranofin to be used 
lor the TrxR assay. An Ie", value of 3 I-IM was obtained (Figure 4.4) hllt, in the literature 
concentratious of less than 1 ,"M were u<ed when treating ~ells with auranolin. 75.1'S In our 
preliminary experiment (Figure 4.5) both 1 11M and 3 I-IM concentrations were tested for lheir 
effects on Thioredoxin Reductase inhibition and were found to have similar levels of 
inhibition. Therefore the I JIM auranofm was used as the standard !realmenl ~oncentralion for 
the rest of the experiments. 
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Figllre 4.4: ICso concentration for allranofin. An MIT assay wa, conducted on the 
\VHCOJ cell line to determi"" the JC~" concentration for auranofin. Cells were plated in % 
well plate, and cultured for 24 hours. Thereafter 10 III of medium containing various 
comoentrations of compounds Were added 10 the wells and in\:ubated for 48 hour,. The linal 
DMSO coocentralion in all the wells was 0.2 %. After 4H bours. MTT reagent was added and 
incubated for 4 hour. followed by ",Iubili ,a[ioll reagent. After 16 hours. the absorbance of 
the plates wa, determined at 595 run. Data analysi' w,,, done on graphpad prism and the data 
is presenled as the mean with error bars represent tbe SLM. 'This data is representative of two 
independent experiments conducted in triplicate. 
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Figun' 4.5: Thioredoxin Reductase inhibition by auranofi n: The effects of aural10fill on 
Thioredoxin Reductase activity were assessed. 6() IIg of total lysate from untreated and 
treated WHe01 cells was a"ayed allhe lime points indicated. This result is representative of 
1\\'0 independent experiments done in duplicate. Mean values were plotted on the graph. The 
OD values which were obtained from the first and ",comj experiment are shown on Table 7 
in the appendix A. 
From the preliminary dala we were ~blc to determine aIld confirm the pre>ence of TaR 
activity in the WHCOI moJeJ cell line. We were also able to estahli,h that 405 run coul<l be 
used to monitor TrxR activity arul finally, we were able 10 confirm that our positive control 
inhibite<11he activity of TrxR, as reported previou,]y. 
To determine the effects ofth<: Il(lvel gold (I) chloride compounds on TrxR activity. ',\"11(:01 
cell, were treale<1 with compounds 93, 94 and 95 and total TrxR activity was measured. The 
gold (I) chloride compounJs were found to inhibit Tr;<;R activity in a time dependent manner. 
very similar to that observed for amanolin (Figure 4.6). 
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Figure 4.6: Det"rmining the effects of the phosphine gold (I) compound~ on total TrxR 
acthily. Total Th.ior~doJ(in R~ductasc (TrxR) was measured (in 60 ~g of protein lysate) as 
de.crihed in materials and mdhud,_ E=yme aClivily waS measured at dijTer~"Il1 lime inlerval, 
over a period of 6{) minutes, This result is representative of two independent experiments 
conducted in duplicate, Mean values were plotted on the graph. The OD values which were 
ubtained lrom the first and second experiment are shown on Table 8 in tile appendix A. 
A fractionation as.ay was condUCted to separak the cytoplasmic 'Thioreooxin R~ducla"" 
crrxR1) from the mitochondrial Thioredoxin Reduclase (TrxR2) and enzyme aClivily was 
then monilored. Similar 10 lhe lolal TaR inhibition. TrxRl inhibition appears 10 be time 
dependent (Figure 4.7). Un
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Figure 4.7: TrxRl inhibitiuD in respuuse to treatment with nOH] phosphine compouud~. 
CylOp]asmi~ Thiol'cdoxin Reducta,e (TrxRl) wa, m~asured (in 6{) Ilg of ~ylOp]asmic pfOlCin 
lysate) '" de,crib.:xl in matcrials and methods_ ~:nzyme activity was mea>ured at dillcr~lll 
tiln~ interval, Over a period of 2 hOOfS, This result is rerre""'ntativ~ of two independent 
experiments conducted in duplicatc. Mcan , 'alucs were plotled on the graph_ The 0)) values 
which were obtain~d from the lirsl and "(>.XlIld ~xperiment are shown on Tahle 9 in th~ 
app'----ndix A. 
All thc thr~~ compound, that were tested, inhibited TrxRI (cytoplasmic T rxR) activity to the 
sall1~ cxtent as auranofin (Figure 4,7), Similar observations were lnade after mea>uring 
TrxR2 (mitochondrial TrxR) octiviry (T'igure 4_~) 
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Figure 4.8; TrxR2 inhihition in n .. pon.e to treatment with novel phosphine compounds. 
Mitodllmdrial Thioredoxin RedllClas~ (TrxR2) was measured (in fi() J.lg of mi tochondrial 
protein Iysat~) as des<:ril>ed in mal~rials and methods. b:nzyme activity was measured at 
different time intervals over a period of 2 hours. This result is representative of two 
ind.;pcndcnl experiments conducted in duplicate, Mean values were plotted on the graph. The 
OD valucs which were obtained from the tlcst and second experiment are shown 00 Table 10 
in the appendix. 
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4.5 Determining Peroxiredoxin protein levels in response to treatment with auranofin 
As was mentioned above, Peroxiredoxin (Prx) is found downstream of TrxR and is reduced 
by Trx and in its reduced form it acts as a ROS scavenger. From our previous result (Fig. 4.6, 
4.7 and 4.8) we showed that treatment of WHCOI cells with compounds 93, 94 and 95 
inhibited TrxR activity. Given this result, we wanted to assess how this inhibition affects the 
oxidation state of Prx. Auranofin was used as a positive control for the optimisation of the 
assay. 
The protein levels of the three Prx isoforms were determined by Western blot analysis, where 
the reduction of Prx results in a shift from a dimer to a monomer. Because we had 
demonstrated that TrxR activity was inhibited by auranofin and our compounds, we 
anticipated that increased levels of the Prx dimer would be observed in cells treated with 
auranofin and the gold complexes, relative to untreated cells. 
Peroxiredoxin 3 (Prx3), which is found in the mitochondria was monitored to determine its 
redox state. WHCO 1 cells were treated with 1 J.1M and 3 J.1M of auranofin for 30 minutes, 2 
and 4 hours and the protein samples were subject to non-reducing Western blotting 
conditions. According to the Sigma technical sheet a 31 kDa protein was expected for the 
monomer. However two very distinct bands of equal intensity were detected and neither of 
the bands was 31 kDa (Figure 4.9). This experiment was conducted four times under different 
conditions and the same observations were made under all four conditions. For the first two 
experiments the primary antibody was dissolved in 2.5 % milk and electrophoresed on a 10 % 
and 12 % gel. For the other two conditions the primary antibody was dissolved in either 5 % 
BSA or 5 % milk and subjected to electrophoresis on a 10 % gel. However the same band 
pattern of equal intensity (as seen on Figure 4.9) was observed under all four conditions. 
80 
Un
ive
rsi
ty 
of 
Ca
p
 To
wn
'"M 3"M 
c 
" " ~ E E ;:, 0 ~ ~ 0 ~ ~ 
n m N • m N • 
52 - ~ - tutrulin 
Figure 4.9: Prx3 dete.: tioll after trea tment with auranofin. \VHCOI cells were trealed 
wilh J I'M and 3 ",M of auranofin for 30 minules. 2 and 4 hours and 20 ",g of protein w,,< 
loaded onto a gel. The DMSO treated cells Were used as a negalive control. Double band, 
(the boltom hand is approximalci)' 46 kDa, wh.ilc the lop band j. 52 kDa) were detected on 
the PIX3 blot This experiment is representative of 4 independent experiments. 
rile protein level. ofllle two cytoplasmic Prx isoforms. PIX l ami Prx2 were aiSD detennined. 
According (0 the Sigma technical sheet, lhe antibody u~d 10 detect Prx 1 should delect a 26 
kDa ITKlOOmer. Therefore lhe dimer or lhe oxidiscd [orm is expected 10 be approximately 52 
kDa. In cell, treated wilh auranofin (J I'M) for various times, no bands comspGnding to the 
expected si;tes ofPrxl Were observcd (figure 4.10). However. an intense band which could 
possibly repreo;ent the oxidi,ed ]i)rm of the protein was obse .... ·cd at 42 kDa (assuming that the 
band detected at 26 kDa is the monomer). However. this seemed unlikely becau<e tfle same 
band WaS detected in the DMSO treated cells (our negative contro l). Even if we assumed that 
the proteins were not migrating at the expectcd molecular weight (since this is a non-reducing 
gel). there i, no dear conversion from monomer to dimer because all the bands at all levels 
(dimer or monomer) are more or Ie" the <ame inten<ity. The result, obtained for thi< 
experiment were diftieult to interpret since we could not be certain that we could 
unambiguou<l)· identify the Pod band. 1bere were also a number of non-specific bands 
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located at the 75 - 95 kDa range that we excluded as possible Prxl bands becallse of the size 
difference. 
kD, 
95 
75 
52 
42 
34 
26 
51 , 
o 
Figure 4.10: Effed of Auranofin on Prxllcveh. WHeOI cdl. were treated with If'\-1 of 
auranofin ror 1, 3 and 6 hour., 20 ILg of cellly.,ate was sllbjected to non-reducing Western 
blorting conditions. 
A similar experiment was conducted to detect Prx2 in auranofin treated cells. Although a 25 
kDa protein (monomer) was expected. many non-specific bands Were observed (Fi~ure 4.11). 
Furthennore. increasing levels of a 34 kDa protein were al", oh.ervcd. The increase in band 
intensity appeared to be time dependent which was assuring. However because the detected 
protein .,iz~ did not correspond to the expected band sizes, there was no way of determining 
whether the protein detected at J4 kDa was a dimer or a monomer. no conclusion could be 
drawn from this result. In conclusion none of the PIX proteins were conclusively detected 
under non-reducing condition.,_ 
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Figure 4.11: Effect or Aura"ofin on 1'n:2 l(no·cls. WlleOI cells were treated with J"M of 
auranofin for 1,3 and (, hours and 20 ",g of cell lysate was >ubjected to non-redllcing \\'CSlcm 
blotting conditions. 
4.6 Dctcding ROS Ie,'cls in response to treatment wilh gold (I) chloride compuunds. 
The TrxR sy,tem regulate. ROS levels through the action ofPrx and thus if TrxR activity is 
inhibited Cas il has Ix:cn shown with our \VHCO j cell line), an increase in ROS levels j , 
expected. In order to further define the effects of the novel gold (lj chloride compounds on 
the Thioredoxin Reductase system, a ROS assay was conducted. As pan of the inilial 
oplimi,ation for the experiment. tile assay was rirst condllCled on twO compound" 
doxorubicin (po,itive control, since we had previou'ly ,hown in our laboratory that this 
compound induces ROS production in WIICOI cells) and compound 93. In Figure 4.12. an 
increa,e in ROS production was observed lor doxorubicin and compound 93 (reated cell, 
concentrations of doxorubicin and compound 93 (Figure 4.13). Similar to the lir, t 
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experiment, a signi ficant increase in ROS production was observed for both concentrations of 
doxoruhicin. In the cells treated with drug 93, there appeared to be more ROS prodllClion at 5 
f'M than at 10 f'M_ 
_ NODCFDA 
_ 01.150 
G;I ooX5~M 
CJ 935fCM 
Figure 4.12: Effect of Doxorubicin and Compound 93 on ROS Ift·cls. WHeOI cell5 Wtlre 
treated with 5 I'M of doxorubiein (dox) and compound 93. The ROS assay was carried OUI as 
described in materials and methods. NO DCFDA (cells treated with DMSO only). DMSO 
(cells trealed with DMSO in the prc.,ence of DCFDA), OOX (positivc control). One-way 
ANOYA analysis was performed using Dunnett's multiple comparison tests, which compares 
all treated cells to DMSO treated cells. p value < 0.0001 (U*)_ 
0 d_' 
-
NO DCFA 0 
0 
• 
-
DM50 0 
• ,,-,-0 
"" 
5 ~M DOX , 
~ Cl 10 flM (0)( 
0 Cl > 5 flM 93 
• I!:J 10~M93 0 
" 
Figure 4.13: Effect of Doxorubicin aod Compound 93 on ROS levels. A ROS assay was 
conducted on WHCOI cells a, descrihed in materials and methods. One-way ANOYA 
analysis was performed using DunneU·., multiple comparison tests, which compares aJl 
treated eells to DMSO treated cells_ p value < 0.0001 (***),0.001 < P <0.01 (*.). 
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In summary, we had established that the positive control was working and that treatment with 
compound 93 induced ROS production. The ROS assay was then conducted on all three gold 
(I) chloride compounds but an effect opposite to that obtained for the first two experiments 
was observed. This experiment was repeated several times and the same observations were 
made on each occasion. 
After several unsuccessful attempts at trying to optimise the ROS assay, a different assay 
approach was developed, where the whole experiment was conducted in 96 well culture 
plates thus eliminating the excess processing of cells. For this experiment the WHCOI cells 
were treated with IX and 2X the ICso concentrations of compounds 93, 94 and 95. However, 
no statistically significant increase in ROS production was observed (data not shown). These 
observations suggested that the ROS reagents may have stopped working and new reagents 
were required. The ROS assay could not be optimised any further due to time constrains. 
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4.7 The ROS scavenger assay 
Due to the technical difficulties encountered using the ROS assay, it was not possible to 
conclusively detennine whether the gold (I) chloride compounds caused ROS generation, 
although several experiments suggested this may be the case. Thus to further investigate the 
involvement of ROS in the response of cells to the gold (I) compounds, the effects of a ROS 
scavenger was tested. This assay involved monitoring cell number using a crystal violet 
staining, after treating cells with a combination of various agents for 24 hours. The crystal 
violet assay was perfonned to measure cell number, since we observed that the ROS 
scavengers interfered with the MTT assay. From the results it is clear that treatment with 
compounds 93, 94 and 95 reduced the number of cells (Figure 4.14) as observed before in the 
MTT assays. The effects of the gold compounds were less pronounced in the presence of the 
ROS scavenger N-Acetylcysteine (NAC). A concentration-dependent effect of the ROS 
scavenger was observed, suggesting that the decrease in cell number correlates with ROS 
generation. 
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Figure 4.14: ROS scavenger as.ay. The WHeOI cell line was !reat~d wilb 3X the IC50 
concentrations for 24 hours in the presence and absence of ROS sca\'enger NAC. Cell 
number was determined using the cry,tal violct stain as described in materials and methods. 
This result is representative of two independent experiments cooouckd in triplicate. One-way 
ANOVA analysis was perionned using Dunnett's multiple comparison tests, which compares 
all treated cells 10 D:MSO treated cells (no drug), 0,001 < P <0.01 (U), 0.0\ < P <0,05 (*). Un
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4.8 Discussion 
In the previous section (Chapter 3), we had demonstrated that the gold compounds 
reproducibly blocked the proliferation of a wide range of cancer cells (and normal 
fibroblasts) at low concentrations. This was associated with a disruption of the cell cycle 
profile, with a significant increase in the S-phase of the cell cycle after 12, 24 and 48 hours of 
treatment. In this section we observed that treatment of WHCO 1 cells with the gold (I) 
chloride compounds was associated with DNA damage (visualised as increased levels of 
phosphorylated H2AX) at 24 hours after treatment for all compounds tested, particularly at 
the higher concentrations of the compounds. At 12 hours, DNA damage was observed for the 
cells treated with 10 IlM of compounds 93 and 95 (Figure 4.1). It has been suggested that the 
presence of phosphorylated H2AX is a result of DNA damage caused by DSB. 141 In addition, 
treatment with the gold (I) compounds also resulted in the induction of apoptosis (visualised 
as PARP cleavage), 24 and 48 hours after treatment (Figure 4.2). Other studies conducted on 
gold compounds such as auranofin and Benzimidazol-2-ylidene gold (I) complexes, have 
demonstrated that gold (I) compounds induce their anticancer activity through the activation 
of apoptosis. 122,139 
In previous studies, the growth inhibitory effects of auranofm (another Gold (I) complex) in 
cancer cells were associated with a significant impairment of the Thioredoxin Reductase 
(TrxR) activity in treated cells?S,138,139 As mentioned previously, the TrxR system in cells 
forms part of an important defensive network that protects cells against oxidative stress, and 
damaging this system, could lead to cell death. 111,122,148 Although our plate reader could only 
measure the absorbance at 405 om and not 412 as recommended for the TrxR assay7S,148, a 
scan of the absorbance spectrum of the TrxR assay product suggested that measuring the 
absorbance at 405 om, would not affect our ability to monitor TrxR activity (Fig. 4.3). 
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Auranofin was used as a positive control during the TrxR activity assay, and before the assay 
was perfonned, an MIT assay was conducted to detennine the ICso value for auranofin. In 
most studies, ICso values less than I J.1M have been obtained after treating other cell 'lines (for 
example leukemia culture cells) with auranofin74,148, however an ICso value of 3 J.1M was 
obtained for the WHCO I oesophageal cancer cell line, suggesting that the sensitivity of 
auranofin may be cell line specific. This is not unexpected. In our experimental system we 
observed that auranofm depleted TrxR activity in the oesophageal cancer cells as reported in 
the literature for ovarian, lung, osteosarcoma, cervical, luekemia and liver cancer cultured 
cells.75,122.148.153 Furthennore, similar to auranofin, our gold compounds also severely 
inhibited TrxR activity in WHCOI cells, reducing total, cytoplasmic and mitochondrial TrxR 
activity levels (Figure 4.6, 4.7 and 4.8). This suggests that the gold compounds (93, 94 and 
95) depleted TrxR activity inside the cells, potentially exposing cells to oxidative stress. 
However, we were unable to show increased levels of the oxidised fonn of the peroxiredoxin 
proteins in cells treated with Auranofin as reported in the literature. Factors such as drug 
degradation, protein degradation, the possibility that the buffers and stock solution were not 
prepared properly as well as problems with protein harvesting, were considered during 
troubleshooting. However the possibility of drug degradation was ruled out as other 
experiments that were conducted using the same drug stocks were successful, furthennore 
treating the cells with fresh stocks of auranofin was not successful. New buffer and stock 
solutions were made up, freshly extracted protein was used in some cases and the assay 
protocol was modified several times, yet the experiment was not successful. We were unable 
to show reproducible elevation of ROS levels in cells treated with the gold complexes, 
although our results were very suggestive for compound 93 (Figure 4.12 and 4.13). In 
contrast, the ROS scavenger, NAC consistently, partially protected the cells from cytotoxicity 
caused by treatment with compounds 93, 94 and 95 (Figure 4.14). Although this protection 
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was not complete, these results strongly suggested that the reduction in cell number caused 
by the gold (I) compounds was mediated in part through ROS. As mentioned previously, 
there is evidence in the literature to suggest that gold (I) compounds induce apoptosis by 
inhibiting TrxR activity and this is associated with an up-regulation of ROS. 122,\38,139 In a 
study conducted on a novel gold (I) compound [Au(d2pypp)2]Cl, bis[1,3-bis(di-2-
pyridylphosphino )propane] gold(l) Chloride, the authors demonstrated that this compound 
induced apoptosis via caspase activation which was associated with the depleted membrane 
permeability transition (MPT) and the loss of the glutathione (GSH) pool, as a result of 
compound built up in the mitochondria. Furthermore, the authors indicated that the TrxR 
system is essential for maintaining the redox state in the cells and that compound 
[Au(d2pypp)2]Cl inhibited TrxR activity causing mitochondrial dysfunction, leading to the 
activation of apoptosis. \38 In addition, a study conducted on auranofin suggested that this 
gold (I) compound induced apoptosis through the alteration of pro- and anti- apoptotic 
protein levels from the Bcl-2 family, rather than via the MPT pore. 148 Here we have 
demonstrated that our compounds inhibit thioredoxin activity and that they seem to induce 
apoptosis 24 hours after treatment, as well as that they may potentially have an effect on 
ROS. Thus for future work, it may be useful to design experiments to investigate how these 
compounds affect the MPT pore, caspase activity and pro- and anti-apoptotic proteins. It will 
also be useful to determine the anticancer properties of these compounds on animal models, 
as the above experiments were only conducted in cultured cells. 
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Chapter S 
Effects of gold (I) compounds on CXCRl and IGFIR knockdown cells 
5.1 Introduction 
Cell surface receptor that mediate cell proliferation, survival and cell migration signals such 
as epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGFR) 
and Interleukin 8 receptor (CXCR2) are over expressed in many cancers, including 
oesophageal cancer.80,82,154-157 There are many reports in the literature that show that these 
receptor systems play an important role in contributing to the survival and proliferation of 
cancer cells (over normal cells).136,158,159 There are a number of studies that have been 
conducted which demonstrate that these receptor are valid targets in the treatment of some 
cancers. 136,157,158 In our laboratory, we have also shown that CXCR2 overexpression 
contributes to oesophageal cancer survival. l60 Since CXCR2 and IGF1R are thought to 
contribute survival signals to cancer cells, we wanted to determine if oesophageal cancer cells 
in which CXCR2 and IGF1R had been knocked down with shRNA, displayed increased 
sensitivity to the gold compounds compared to the wild type cells. 
5.2 Results 
Using IGF1R and CXCR2 stable knockdown cells that were established in our laboratory, 
cell viability assays were conducted to determine the effects of phosphine gold (I) 
compounds on these cell lines. The presence of knockdown was confirmed by western blot 
analysis where reduced levels of IGF1R and CXCR2 protein levels were detected in the 
WHCOI and WHC06 (result provided by Dr Luke Esau) knockdown cell lines, compared to 
cells where scrambled shRNA had been transfected (Ctrl shRNA) (Figure 5.l and 5.2). 
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Afi~r 'tabl ~ knockdown had bccn confirmed, MTT a'say' wcrc condllctcd on thc wlleOI 
parental cells, WHCOI Control (etrl) ,hRNA c ~ II" WIIC01 CXCR2 shRNA knockdown 
cclls and WIICOI lor'1R ,hRNA knockdown c~lls, as well as on the WHC06 parental cells 
and rcspective knockdown cel l<. 
kD, 
135 
95 
52 
42 
52 -
WHcal 
- IGF1Rp 
_ CXCR2P 
_ !J-tubulin 
Figure 5,1: CXCR2 and IGF1R ,j"blc knockdown in the \\'lICU1 cell line. Intcrkukin S 
receptor (CXCR2) beta and In'ulin-lik ~ growlh factor -I receptor (IGFIR) beta knockdown 
was detcrmincd in thc WHeOI ccllline, 20 118 of protein waS clcctrophore,cd. 
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WHC06 
WHC06 
< 
Z 
~ 
< ~ Z • 
~ ~ 
~ ~ 
• ~ 
- CXCR2 
< • 
" 
~ 
- IGFtRj) 
- J3-Tubulin tHubulin 
Figure 5.2: CXCR2 and ICF1R stable knockdown in the WHC06 cell line. 'Illis r~sult 
wa., oblained frum a PhD slUd~llt ill our laborat[).-}, Inl~rl~lIkin 8 r~~eplur (CXCR2) bela and 
Insulin-like growlb j;lclOr -I receptor (IUFIR) kta kllockdown was lklerrni,...,d in 1m, 
WHC06 cell line. 
A sligbt decr~ase in lhe IC, " concentration was ob,er>'ed in lhe CXCR2 kIJ()~kdown cells; 
oowever !hi., d~crease was not significant because the 95 % CI [)j'tbe c[)I11ml and knockdown 
c~lIs overlap (T abl~ 5, I a), The same observatioll" were made for lhe CXCR2 kIKJ~kdown ~cll 
lin~s tr~ated with compound 94 (Table 5.lb) and compound '15 ('Jable 5.1 c). 
An IC," c[)J1centraliun uf 15.59 ~).1 wa.' observ~d f[)f tl..., WHCOI celli treated wilh 
compound 93 (Table 5,2a). and in tI", IGFIR knockoown ~ells . an increase in Ihe IC," 
concentratiun was observed jor both lhe WHCOI and WIIC06 knockdown cell wflen 
compared l[) tbe control cells. Th~ sam~ observati[)llS wer~ mad" for Ihe cell, lrealcd wiill 
compound 94 (Table 5.2b) and c{Jmpound '15 (Table 5,2c). 
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In principle treating the knockdown cells with the phosphine gold (I) compounds was 
hypothesized to cause either a synergistic or additive effect, where knockdown of the 
receptors would reduce the cancerous phenotype of the cells and treatment with the 
chemotherapeutic agent would thus caused the cells to be more susceptible to apoptosis. 
However this was not the case as seen with our data. 
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Table 5.1 
WHC01 and WHC06 CXCR2 shRNA knockdown cells treated with phosphine gold (I) 
compounds. MIT assays were conducted on WHCO 1 and WHC06 parental cells, Control 
(Ctrl) shRNA cells, and CXCR2 shRNA knockdown cells. Tables show ICso values obtained 
after treatment with (a) compound 93, (b) compound 94, (c) and compound 95. These results 
are representative of two independent experiments conducted in triplicate. 
Cell line ICso (J.LM) 95 % CI 
Compound 93 
, 
.\VliCOf, '~1"::':':~ 1;,\:~;··~:LL:t~~~" ' .""i:'~~T, " " 10.51 to 14.49 
WHCOI Ctrl shRNA 13.07 11.05 to 15.46 
\vfIcdlcXCR2IJ·~~:.(:~";}:' 
• • .:; "," ,I 
," ," 11.31 9.05 to 14.12 
WHC06 12.37 10.24 to 14.96 
WHC06'etrlsh:RNl\< ,> b:, .·.·14.08 I,: 9.48 to 20.91 r 
WHC06 CXCR21J shRNA 11.63 8.70 to 15.54 
95%CI 
Compound 94 8.46 to 10.77 
9.73 to 11.12 
8.72 to 9.87 
9.03 to 12.40 
10.23 to 12.93 
WHC06CXCR2pshRNA 11.80 10.21 to 13.64 
Compound 95 
Cell line ICso (JIM) 
,. 
5.27 to 9.28 
WHCOl Ctrl shRNA 9.59 7.92 to 11.61 
7.52 to 9.55 
WHC06 6.91 4.54 to 10.50 
, 9.5Tto 12.08 
WHC06 CXCR21J shRNA 11.31 9.65 to 13.24 
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Table 5.2 
WHCOl and WHC06 IGFlR shRNA knockdown cells treated with phosphine gold (I) 
compounds. MIT assays were conducted on WHCOI and WHC06 parental cells, Control 
(Ctrl) shRNA cells, and IGFIR shRNA knockdown cells. Tables show ICso values obtained 
after treatment with (a) compound 93, (b) compound 94, (c) and compound 95. These results 
are representative of two independent experiments conducted in triplicate. 
Compound 95 Cell line ICso (pM) 95%CI 
H).04to 24.21 
WHCOI Ctrt shRNA 8.16 7.35 to 9.07 
9.24 to 17.73 
WHC06 8.22 7.64 to 8.85 
7.95 to 11.34 
WHC06 IGFIRf3 shRNA 16.16 12.87 to 20.28 
Cell line ICso (pM) 9S oAt CI 
Compound 94 r,""I(,,""~ ' ... i.; W«C6i'··;i;·:'}",~:;;;J~;::,·;~!~~')ft;F;jf:~~~~ .. ',., .. " ,.,' .....• ,.' 9.43 'to 11.37 
WHCOI Ctrt shRNA 7.41 6.96 to 7.89 
, 
WHeal IGFIRf3$hRNA ." 8.57 7.65 to 9.61 
WHC06 8.87 7.88 to 9.99 
8.23 to 9.75 
WHC06 IGFIRf3 shRNA 10.93 9.99 to 11.97 
Compound 95 Cell line ICso (pM) 95%CI 
10.23 to 14.49 
WHCOI Ctrt shRNA 8.48 7.13 to 10.08 
, 
8.54 to 10.29 
WHC06 10.78 9.26 to 12.54 
8.56 to 11.28 
WHC06 IGFIRf3 shRNA 11.34 9.96 to 12.91 
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5.3 Discussion 
When CXCR2 and IGFIR knockdown cells were combined with novel compounds, no 
improvement in efficacy was observed. Thus we can conclude that combination treatment 
with compound 93, 94 and 95 did not lead to any synergistic or additive effect instead the 
compounds were observed to be slightly antagonistic. 
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Conclusion 
In their review article, Urig and Becker (2006) highlighted several Thioredoxin reductase 
(TrxR) inhibitors that have been identified and found to be cytotoxic against a wide range of 
cancers. 161 Here we have identified three potential novel inhibitors of TrxR, which could 
prove to be therapeutically beneficial in the treatment of squamous cell carcinoma of the 
oesophagus. In the same review, the authors summarised various ways in which TrxR 
inhibitors could induce their effects and these included, TrxR inhibition, a decrease in tumour 
volume, an increase in ROS production, cell cycle inhibition, the induction of apoptosis and 
many others. 161 In this study we have shown that the novel gold (I) chloride compounds 93, 
94 and 95 inhibit cell growth in a time- and dose-dependent manner (Figure 3.2). Although 
we were unable to show that all three compounds induce ROS production, the presence of 
ROS was strongly suggested for all three compounds using the ROS scavenger assay (Figure 
4.15), where recovery in cell number was observed upon treatment with increasing 
concentrations ofNAC. From analysing the cell cycle profile we showed that treatment with 
the gold (I) compounds causes a G 1 cell cycle arrest (Figure 3.3). Furthermore 
phosphorylated H2AX, an indicator of DNA damage, was detected after treatment with 
compounds 93, 94 and 95 (Figure 4.1). By conducting a PARP assay (Figure 4.2), we were 
able to deduce that the gold (I) compounds induce apoptosis in a time- and dose-dependent 
manner. Despite the non-selective killing effect observed for these compounds, the wide 
spectrum of anticancer properties they present points to their potential as therapeutic agents. 
However, it would appear that these novel compounds do not present any advantages over 
well know chemotherapeutic agents like auranofin. 
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Prospective work 
To further explore the relationship between ROS production and the inhibition of 
Thioredoxin reductase activity. The Peroxiredoxin oxidation state should be investigated by 
Western blot analysis using new antibodies, preferably those that have been used in 
publication that look at Peroxiredoxin oxidation state using non-reducing Western blotting 
conditions.126,148 Furthennore additional optimisation is required for the ROS assay to 
conclusively establish the effects of compounds 93, 94 and 95 on ROS levels. 
Attempts to detect phosphorylated H2AX at earlier time points (2 - 4 hours) using the FOCI 
assay which quantitates levels of phosphorylated H2AX foci caused by DSBs, were made. 
Although a slight increase in the number of foci was observed in the treated cells when 
compared to DMSO treated cells, this data could not be quantitated because the foci appeared 
in clusters and thus individual foci were indistinguishable. Further more some cells had more 
staining than other and thus quantitation could have led to obscure and subjective results. The 
data was analysed by immunofluorescence. However some publications have shown that this 
assay could be conducted by flow cytometry thus further optimisation of this assay by flow 
cytometry could be attempted. This would allow for a more sensitive detection of DNA 
damage at early time points. 
Cyclins and cyclin dependent kinases (CDK) that are involved in the G liS cell cycle arrest 
(for example, CDK2/cyclin A for S phase and CDK2/cyclin E for Gl) should be detected by 
Western blot analysis to assay for any changes in protein levels, to characterise the 
deregulation in the cell cycle that was observed. 
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To support the data obtained from the P ARP assay and to confirm that the compounds do 
induce apoptosis, an independent assay like the Caspase 3/7 activity assay should be 
conducted. 
Experiments to determine the cancer growth inhibitory properties of these compounds were 
conducted in cultured cells and therefore for future work, the anticancer properties of the 
compounds should be investigated in animal models. 
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Appendix A: Tables and Protein Marker 
Table 1 General treatment table: The following treatment table was used to treat cells with 
compound 93, 5-fluorouracil, auranofin, novel platinum compounds and ligands. All 
compounds were dissolved in DMSO to make 100mM stock solutions which were stored at -
20°C. 5-fluorouracil and auranofin were stored in the dark. 
(1x) JIM (lOx] JIM Preparation of lOx pre-stock 
A 0 0 98~IDMEM 2~IDMSO No drug 
B 0.1 1 98~IDMEM 1~IDMSO 1~1 (O.lmM drug dilution) 
C 1 10 98~IDMEM 1~IDMSO 1~1 (lmM drug dilution) 
D 5 50 98~IDMEM l.5~IDMSO 0.5~1 (10mM drug dilution) 
E 10 100 98~IDMEM 1~IDMSO 1~1 (IOmM drug dilution) 
F 50 500 98~IDMEM 1.5~IDMSO 0.5~1 (l00mM stock) 
G 100 1000 98~IDMEM 1~IDMSO 1~1 (l00mM stock) 
H 200 2000 98~IDMEM NoDMSO 2~1 (100mM stock) 
Table 2 Treatment table for compound 94 and 95: 50mM stock solutions of compound 94 
and 95 were made up in DMSO and stored at -20°C. The following treatment table was used 
during MIT assays. 
(1x) JIM (lOx) JIM Preparation of lOx pre-stock 
A 0 0 98~IDMEM 2~IDMSO No drug 
B 0.1 1 98~IDMEM 1~IDMSO 1~1 (O.1mM drug dilution) 
C 1 10 98~IDMEM 1~IDMSO 1~1 (ImM drug dilution) 
D 5 50 98~IDMEM l.5~IDMSO 0.5~1 (10mM drug dilution) 
E 10 100 98~IDMEM 1~IDMSO 1~1 (10mM drug dilution) 
F 25 250 98~IDMEM l.5~IDMSO 0.5~1 (50mM stock) 
G 50 500 98~IDMEM 1~IDMSO 1~1 (50mM stock) 
H 100 1000 98~IDMEM NoDMSO 2~1 (50mM stock) 
Table 3 Treatment table for Doxorubicin: The following treatment table was used to treat 
cells with Doxorubicin (Dox) during MIT assays. 50mM stock solution of Dox was made up 
in dH20 and stored in the dark at -80°C. 
(h) JIM (lOx] JIM Preparation of lOx pre-stock 
A 0 0 98~IDMEM 2~IDMSO No drug 
B 0.1 1 98~IDMEM 1~IDMSO 1~1 (O.1mM drug dilution) 
C 0.5 5 98~IDMEM 1.5~IDMSO 0.5~1 (ImM drug dilution) 
D 1 10 98~IDMEM 1~IDMSO 1~1 (ImM drug dilution) 
E 5 50 98~IDMEM 1.5~IDMSO 0.5~1 (10mM drug dilution) 
F 10 100 98~IDMEM 1~IDMSO 1~1 (10mM stock) 
G 20 200 98~IDMEM NoDMSO 2~1 (lOmM stock) 
H 50 500 98~IDMEM 1~IDMSO 1~1 (50mM stock) 
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Table 4 
Cisplatin treatment table 
The following treatment table was used to treat cells with cisplatin for MIT assays. L6mM 
stock solution of cisplatin was made up in IXPBS and stored at 4°C. 
P<epa<atiaR aflOX U-It""" 
Ihll'\\ 110>.1,,'1 t. 6mMstock(~1) DMEM(~I) 
A ,;, 
" 
0 '00 
B lU , 0.' w, 
, W 1.25 98.H 
D I lJ 
"" 
•. , 93.8 
, 1 j 
"" 
., OM 
, y;, 
"" 
18.8 81.2 
G ", 000 37.5 62.5 
H . 5(: "00 93.8 ., 
Table 5 
Stati5tical analysis for cdl cycle profile n'5ults (first experiment) 
Statistical analysis was done on the S phase only. where DMSO treated cells were compared 
to cells treated with doxorubicin and the gold (I) compounds for 12,24 and 48 hours. This 
experimem was conducted in triplicate and the replicas for each treatment condition were 
used to calculate the p-wlucs using the student t-test. The Mean and st!llJdard deviation 
(Stdev) [0.- each treatment point are also included in the tahle. '" indicates significance p<O.05 
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Table 6 
Statistical ana lysis for « II cycle prof"tle resul ts (second experiment) 
Statistical analysis was done on the S phase only, where DMSO trealed cells Were compared 
10 ~dls Ireal~d with doxorubicin and Ihe gold (I) compounds for 12, 24 and 48 hour.>. Thi, 
~xp"rimenl was condl1CI~d in triplicale and th~ r"Plica, for ~ach Ireatm",,1 condition w~re 
us~d to calclllaw th~ p-values u;;ing the stlld~nt I-Iesl. Th~ M~an and standard d~Yiation 
(Stdev) for cach treatment point are also includ~d in lhe tablc. * indicates significanc~ p<O.05 
Sta';"i<al .n.l~', i, (TTF~<;T) 
'" ". 
, 
.8 h 
' leon Std<v -valu. M<>Il S,d<,' ,'oh,t ~Ican ~hk, -,·alu. 
D;\ISO 38.2 
" 
53 .6 U 25.1 
" 51'.'1 DOX 55.9 11,1 O.l5828D 7D.9 1.3 D.(Kl I419' M.' 
" 
D.Ml11' 
5 fL\193 70.3 
" 
0,004282' 71.4 U 0.001041' 37.1 
" 
0, 001 457' 
10 1"1 ~J 
'" 
U D,DD8634* 78.2 1.3 0.002.l33' M.3 
" 
0.000876* 
'.oJ'-1 9~ 49.6 ,. 0,043345' 73.2 
" 
0.001815' 48.1 ,., D.OO2264· 
12 I'M '4 67,4 
"' 
D,DD7419* 77.$ He' O.03163b' 7L7 
" 
OJ)(1046I ' 
_t~195 ~14 •. , 0.075162 59,5 '.0 0.257145 28.7 
" 
0.271957 
101l~1~5 68,6 :1.5 D,DDl879· &4,9 U O.0038b5 ' 5U 
" 
0.002700' 
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Table 7 
Thloredoxin Reducta~e inhibition by auranofrn 
The effects of aurnnofin on Thioredoxin Reductase activity wo:re assessed on the WHeOI 
cell line as described in the mat~rials and methods. This result is representative of two 
independent experiments conducted in duplicate (Experiment I is highlighkd in blacl and 
experiment 2 in green). 
~ " ffi- ~ DMSO , 
'ili " 
Aur.nolin 1 fL\I 1-''' ~ - t., ;l " ~ " f-",uranofin 3 1';\1 ~ ~ ~~ , D;\\SO \'li' 
" 
, , 
, , , 
Auron.fin 1 1''' ~ "C " " , , 
" Aur.nollD 3 ~)\ 
" " 
, 
" 
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Table 8 
Determining the etTects of the phosphine gold (l) compounds on total TrxR activity. 
TOlal lbioredoxin Reductase (TaR) was measun:d (in 60 fig of prQ{ein lysate) as described 
in materials and methods. Enzyme activity was measun:d at diffen:nt time intervals over a 
period of 60 minliles. Ibis reslill is representative of m'o independent experiments conducted 
in duplicate (lOxperimcnt I is highlighted in black and experimenl2 in green). 
5 min 10 min 
, iii[ 
D;\ISO J'ili' ~ iK ii<ii: iK "" ~ "~ ,. '" , 
AUrlloofin t ,.." , , , 
~ ~ , 935 1''' , , , ; ) .~: ;;:; 
946 I'M , ,,", 
"" '''"" 
,~ 
em {I." O. , ~ , C' .. \4~ 
95 SI,M ~ , , , '" " " 
~., , D;\l S0 , ,,,,, , , , 
l'A 3S 
Auraoofin I ... '1 , , -~ " , , 
935)'-.\1 
ilk "-"'-
*= 
--"'" '" 
94 (i ... '1 ~ 
,CD ~ --""-, 
95 5 fk\! 
* 
HC ~ 
"'" 
,- , . 
(.,. ", 
I 
, 
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Table <j 
T nRl inhibition in re.ponsc to trClttmenl with novel phosphine compounds. 
Cytoplasmic Thioredoxin Reductase (frxRl) was measured (in 60 ~g of cytoplasmic protcin 
lysate) as describcd in materials and methods. Enzyme activity was measured at different 
tim" intervals ovcr a period of 2 hour~. This result is representative of two independent 
experiments conducted in duplicatc (Experiment I is highlighted in black and experiment 2 in 
green). 
, Ii, 
, C'."" I."ll' ~ ~ , '" I !n1S0 
" 
O.Hl 
" n , ", I r ,-' 
, 
Au,",wl,,, I " ~ '1 o St' , , "~ "'" n , , ~ ~ ~9:< 5 I"t "'" , , " " ~ , 
9~ 61,~1 , , n , ~ 955 .... ' 1 ~ ~ ~ , 
" 
, 
, 
,"if ii' 
, , 
, 
ili: 
%.it 
, , 
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-Table 10 
TrxRl inhibition in respume 10 treatrnl"nt with novel phosphine compounds. 
Mitochondrial Thiocedoxin Redu<:ta.5e (TrxR2) was measured (in 60 fig of mitochondri al 
protein lysate) as described in materials and methods. Enzyme acth'ify was measnred at 
different lim~ intervals Over a p"riod of 2 hours. This result is representative of two 
independent experiment~ condocted in dllplicale (Experirocnt I is highlighted in black and 
experiment 2 in green). 
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Figu", 1: Spectrant Multicolour Broad Range Protein Ladder (# SM1841). This protein 
ladder was used in Western blot analysis and it is suitable for detecting proteins of 10 to 260 
kDa on 4 % to 20 % gels. 
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Appendix B: Solutions 
B.1 Tissue culture 
lOx PBS lL 
80gNaCI 
2gKCI 
11.Sg Na2HP04'7H20 
2g KH2P04 
Make up to 1 L with dH20 
Store at room temperature and at 4°C once diluted to Ix PBS 
Heat Inactivated Foetal Calf Serum (FCS) 
Heat FCS for 30 minutes at S6°C 
Store at -20°C for long term storage and at 4°C once opened 
Penicillin I streptomycin solution 
Add S million units of Penicillin G Sodium (Highveld Biological) to Sml PBS 
Add Sg 2l4S Streptomycin Sulphate (Highveld Biological) to lSml PBS 
Combine the two solutions and make up to SOOml with PBS 
Store at -20°C 
Complete DMEM 
4S0mlDMEM 
SOmlFCS 
Sml Penicillin and Streptomycin (PIS) 
Store at 4°C 
Trypsin-EDTA 
O.Sg trypsin 
8gNaCI 
l.4Sg Na2HP04'2H20 
0.2gKCI 
0.2g KH2P04 
lOmM EDTA (PH 8) 
Make up to lL with PBS 
Store at -20°C for long term and at 4°C once in use 
Mycoplasm staining solution 
O.SJ.1g1ml Hoeschst No. 332S8 diluted in Hanks Buffered Saline Solution (without phenol red 
or sodium bicarbonate) 
Store at 4°C covered with foil 
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Hanks Buffered Saline Solution (without phenol red and sodium bicarbonate) 
5.4mMKCI 
O.3mM Na2HP04 
O.4mM KH2P04 
1.3mMCaCh 
O.5mMMgCh 
O.6mMMgS04 
137mMNaCI 
5.6mM D-glucose 
pH 7.4 
Make up to 1 L with dH20 
Store at 4°C 
Mycoplasma fIXative 
1 part glacial acetic acid and 3 parts methanol 
Mycoplasma mounting fluid 
22.2ml O.lM citric acid 
27.8ml O.2M Na2HP04'2H20 
50ml glycerol 
pH 5.5 
Store at 4°C 
B2: MTT assay 
MTT reagent Smglml 
Weigh out 100mg MIT 
Add 20ml sterile PBS in TC hood 
Vortex the mixture and incubate in the water bath at 37°C for 15 minutes 
Filter the solution into another 50ml tube through a O.2J.1m filter 
Wrap the solution in foil and store at 4°C 
Solubilisation reagent 
Dissolve 50g of SLS in 500ml of dH20 
Add 153.2J.11 of conc. HCI 
Store at room temperature 
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B3: Cell Cycle 
RNAse lOmglml 
Dissolve pancreatic RNAse (RNAse A) in 10mM Tris.Cl pH7.5 and 15mM NaCI 
Heat at 100°C for 15 minutes and cool slowly to room temperature 
Make aliquots and store at -20°C 
PI (propidium iodide) staining solution (make up fresh always) 
0.1% Triton XI00 
2mMMgCl2 
100mMNaCI 
10mM PIPES buffer 
10p.glml Propidium iodide 
Make up to 50ml with dH20 
B4: Western blot 
RIPA buffer 
150mMNaCI 
1% Triton XI00 
0.1% SDS 
10mM Tris pH 7.5 
1 % Na deoxycholate 
Make up to 200ml with dH20 
Store at 4°C 
Add Protease inhibitor and phosphatase inhibitor fresh every time before use 
Sx loading buffer 
15.1g Tris 
72g glycine 
Dissolve in 50ml dH20 
pH to 6.8 
add 5g SDS 
Make up to 100ml with dH20 
Store at room temperature and heat before use 
Sx Laemmli dye 
200p.1 5x loading dye 
100p.1 J3-mercaptoethanol 
100p.1 0.025% Bromophenol blue 
Store at -20°C 
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1M Tris pH 8.8 
60.Sg Tris 
Add 300ml dH20 
pH to 8.8 
Make up to SOOml with dH20 
Autoclave 
Store at room temperature 
10% Resolving gel 
S.Sml dH20 
7.SmIIM Tris pH 8.8 
200~1 10% SOS 
6.7m130% Acrylamide (Sigma) 
400~1 10% APS 
40~1 TEMEO 
15% Resolving gel 
2.2ml dH20 
7.5m11M Tris pH 8.8 
200~1 10% SOS 
10mi 30% Acrylamide (Sigma) 
400~1 10% APS 
40~1 TEMEO 
4% Stacking gel 
7.3mldH20 
1.2Sml 0.94M Tris pH 6.7 
I 00~1 10% SOS 
1.3ml 30% Acrylamide (Sigma) 
120~110% APS 
12~1 TEMEO 
lOx Running buffer 
29gTris 
144g Glycine 
109 SOS 
Make up to I L with dH20 
Store at room temperature 
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lOx Transfer buffer 
144g Glycine 
38g Tris 
Make up to lL with dH20 
Store at room temperature 
lOx Tris Buffered Saline (TBS) 
60.5g Tris 
87.6gNaCI 
pH 7.5 
Make up to 1 L with dH20 
Store at room temperature 
Stripping buffer 
l.4ml beta-mercaptoethanol 
40mllO% SDS 
12.5mllM Tris pH 6.7 
Make up to 200mi with dH20 
Store at 4°C 
BS: Thioredoxin reductase 
Mitochondrial isolation buffer 
20mM HEPES-KOH 
lOmMKCI 
1.5mMMgCh 
ImMEDTA 
ImMEGTA 
O.25M Sucrose 
Add lOOml of dH20 
pH 7.5 
Make up to 200mi with dH20 
Filter sterilise and store at 4°C 
NOTE: CHAPS and protease inhibitor should be added fresh on the day of the experiment 
125 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Lysis buffer 
40mM HEPES·KOH 
50mMNaCI 
1mMEDTA 
1mMEGTA 
Add 100ml dH20 
pH to 7.4 
Make up to 200ml with dH20 
Filter sterilise 
Store at 4°C 
NOTE: CHAPS and protease inhibitor should be added fresh on the day of the experiment 
PE buffer 
100mM Potassium phosphate 
10mMEDTA 
pH7 
Make up to 200ml with dH20 
Autoclave / Filter sterilise 
Store at 4°C 
B6: ROS 
DCFDA 
Make up fresh from primary stock 
Molecular weight = 487.26g1mol 
Primary stock = 50mM in DMSO (50mg in 2.05ml) 
Kreb's ringer (KR) buffer 
Table 5 KR buffer solution table: A stock solution without glucose must be made up, pH to 
7.4, filter sterilised and stored at 4°C. Glucose must be added fresh on the day of the 
experiment. 
Reagent Molar mass Final conc. Mass for lL Vol. For Vol. For 500ml 200ml 
NaCl(5M) 57.75 110mM 6.35g 11ml 4.4ml 
KCl (lM) 74.56 2.6mM 0.19g l.3ml 0.52ml 
MgS04(1M) 120.36 1.2mM 0.14g 0.6ml 0.24ml 
KH2P04 (1M) 136.09 1.2mM 0.16g 0.6ml 0.24ml 
NaHC03 84.01 25mM 2.10g 12.5ml 5ml (1M) 
Glucose 180.08 IlmM 1.98g 0.99g 0.396g 
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Crystal Violet 
1 % crystal violet 
50% Methanol 
Store at room temperature 
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